**CURRICULUM VITAE**

**Martin Laurence Lee, PhD, CStat, CSci**

**3941 Eureka Drive**

**Studio City, CA 91604**

**Phone: (818) 807-9365**

**Fax: (818) 769-2880**

DATE OF BIRTH: June 8, 1953

BIRTHPLACE: London, England (U.S. Citizen)

MARITAL STATUS: Married (two sons)

**EDUCATION** 1974 B.A., Mathematics, University of California at Los Angeles (Summa cum Laude)

1975 M.S., Biostatistics, University of California at Los Angeles

1979 Ph.D., Biostatistics, University of California at Los Angeles (minor in Biological Chemistry)

**EXPERIENCE**

2005 – 2019 Harbor Healthcare Systems

CONSULTANT

Provide statistical modeling of health outcomes data and develop novel approaches for assessing physician quality in terms of care of workplace injuries

2005 − 2012 Inspiration Biopharmaceuticals

CONSULTANT

Responsible for clinical trial and activities for a venture-capital supported biotech company involved in novel biological products for the treatment and care of individuals with hemophilia.

2001 − Present Prolacta Bioscience, Inc.

VICE PRESIDENT, CLINICAL RESEARCH AND DEVELOPMENT/SENIOR VICE PRESIDENT, DATA ANALYTICS

Responsible for all research and development, as well as regulatory activities for a venture-capital supported start-up intending to provide human breast milk for very low birth weight premature neonates.

2001 – Present Charles R. Drew University of Medicine and Science, Dept of Endocrinology

PROFESSOR, INTERNAL MEDICINE

Support group of medical researchers by providing statistical consultation and education.

2001 – 2007 Harbor-UCLA Medical Center, UCLA Vaccine Research Institute

DIRECTOR, BIOSTATISTICS AND DATA MANAGEMENT

Oversee group of biostatisticians and programmers working on vaccine research studies under government and commercial funding.

1998 – 2001 Baxter Healthcare Corporation, Hyland Immuno Division

DIRECTOR, CLINICAL STRATEGY AND BIOSTATISTICS

Responsible for biostatistics group in Los Angeles and Vienna facilities. Organize and oversee various new studies of existing products and strategize clinical research for new products.

1994 - Present Sepulveda VA Medical Center

SENIOR HEALTH STATISTICIAN

Consultant to a large group of physicians/researchers from Southern California VA Medical Centers with respect to research on health outcomes, quality of life and primary care.

1986 - Present International Quantitative Consultants, Inc.

PRESIDENT

Set up and manage consulting company to support clinical, statistical, and regulatory needs of various biologic, drug and device companies, particularly those in the biotechnology sector. In addition, serve as an EXPERT WITNESS for numerous healthcare fraud cases involving Medicare/Champas (for the U.S. Department of Justice), worker’s compensation (FBI), various state health insurance agencies (California, West Virginia, Florida, New York, etc.), as well as patent infringement and product liability cases. Work has included depositions and expert testimony in hearings and trials

1994 - 1996 VivoRx, Inc.

VICE PRESIDENT, CLINICAL AND REGULATORY AFFAIRS

Responsible for clinical and regulatory programs for a small, biotech company working on encapsulated islet cell transplantation for the treatment of type 1 diabetes.

1992 - 1996 MedClone, Inc.

DIRECTOR, REGULATORY AND CLINICAL PROGRAMS

Responsible for all regulatory, clinical and biostatistical programs for a venture capital-supported company working on the treatment of various autoimmune diseases using monoclonal antibody therapy.

1991 – present EXPERT WITNESS

Serve as an expert statistical witness in numerous healthcare fraud cases for both the US Department of Justice, and numerous states Department of Justice. Testified in court (trials and administrative hearings) and provided depositions. Also, have worked on cases for the EPA and FTC as a statistical expert, along with product liability and patent infringement cases.

1990 - 1991 Trancel Corp.

DIRECTOR, CLINICAL AFFAIRS

Responsible for all pre-clinical and clinical programs for a venture capital supported company in the business of encapsulated cellular transplants.

1989 - 1990 Baxter Healthcare Corporation, Technology & Ventures Division

VICE PRESIDENT, REGULATORY AFFAIRS/QUALITY ASSURANCE/CLINICAL PROGRAMS

Responsible for all compliance activities for company manufacturing gastroenterologic and urologic devices. Responsible for preparation and submission of IDEs, PMAs, and 510(k)s, as well as foreign submissions. Also oversee quality assurance activities. Direct clinical research program worldwide. Supervise department of nine individuals.

1979 - 1989 Baxter Healthcare Corporation, Hyland Division

DIRECTOR, MEDICAL AFFAIRS

Responsible for worldwide direction of clinical research programs for company manufacturing blood proteins (biologics). Includes identification, design, implementation and finalization of clinical trials. Prepare IND and NDA/PLA submissions for FDA and maintain regulatory files. Also provide marketing research support to suggest new directions for existing products. Consult on technical Quality Assurance problems.

Supervise department of six individuals. Previous positions held included ASSOCIATE DIRECTOR, MEDICAL AFFAIRS; MANAGER, CLINICAL DEVELOPMENT; STAFF ASSOCIATE (Clinical Development); and BIOSTATISTICIAN.

1979 - Present University of California at Los Angeles, Fielding School of Public Health

ADJUNCT PROFESSOR

Teach courses in beginning biostatistics, clinical research, and experimental design to public health, medical, and nursing students. Courses include: Introduction to Biostatistics (required course for MPH in Public Health and elective for undergraduates in the biological sciences); Applied Biostatistics; Introduction to Pharmaceutical Statistics; and Introduction to Statistical Methods for Clinical Trials.

1973 - 1979 University of California at Los Angeles, University of Southern California, California State University at Northridge, California State University at Los Angeles

Various statistical consulting positions held at UCLA School of Medicine and Dentistry and USC Shock Research Unit (Hollywood Presbyterian Medical Center). Teaching positions held at UCLA, Cal State Northridge and Cal State Los Angeles.

**PATENTS**

Methods for testing milk (E. Medo, M. Lee, D. Rechtman): U.S. Patent 7,943,315 (issued 5/17/11)

Human milk compositions and methods of making and using same (E. Medo, M. Lee, D. Rechtman and J. Fournell): U.S. Patent 8,545,920 B2 (issued 10/1/13)

**HONORS AND AWARDS**

Phi Beta Kappa, 1974

NIH Traineeship, 1974-75

Regents' Scholarship, 1973-74

Pi Mu Epsilon, National Mathematics Honor Fraternity

Delta Omega, National Public Health Honor Fraternity

Dean's List, eight times as an undergraduate

United States Public Health Service (USPHS) Trainee, 1974-75

Regent's Fellow, 1976-78

UCLA Alumni Association Scroll Award, 1979

Who's Who in the West, 1984-6

Baxter/Travenol Marketing Consistent Publication Award, 1986-88

Who's Who in Emerging Leaders in America, 1987

Who's Who in the World, 1990

Faculty of the Year, UCLA School of Public Health, 1992-93, 2001

Chartered Statistician, Royal Statistical Society, 1993

Best Contributed Paper Award, Honorable Mention, American Statistical Association, Biopharmaceutical Section, 2003

Chartered Scientist, The Science Council/Royal Statistical Society, 2009

Sentinel Award, Association of Certified Fraud Specialists, 2010

Certified Fraud Specialist, Association of Certified Fraud Specialists, 2010

Albert Nelson Marquis Lifetime Achievement Award from Marquis Who’s Who, 2018

Fellow, Institute of Biomedical Sciences, 2020

**PROFESSIONAL MEMBERSHIPS**

American Statistical Association

Biometrics Society

Institute of Biomedical Sciences, Fellow

International Society for Research on Human Milk and Lactation

International Society on Thrombosis and Hemostasis

Royal Statistical Society, Fellow

**TEXTBOOKS**

Lee ML and Strand V. (eds.) Intravenous Immunoglobulins in Clinical Practice, Marcel Dekker, Inc., 1997

Afifi A, Lee ML, Cobb G. An Electronic Companion to Biostatistics. Cogito Learning Media, 1998

**MEMBER, JOURNAL EDITORIAL BOARD**

Implementation Science, 2006-present

**PUBLICATIONS (peer-reviewed)**

Lee ML. Inverse regression (letter), Technometrics, 21, 275, 1979.

Lee ML, Kantrowitz JL, and Ellis J. An application of the negative binomial distribution to a problem in microbiologically clean area testing, J. Parenteral Science and Technology, 36, 237-246, 1983.

Lee, ML, Maglalang EA, and Kingdon HS. An effect of predilution on potency assays of Factor VIII concentrates, Thrombosis Research, 30, 511-519, 1983.

Heldebrant C, Kleszynski R, Short M, Aronson D, Brown L, Jacoby G, Lee ML, Thomas D, Barrowcliffe T, Howell I, Johnson RC. Assay of AHF concentrates and standards: failure to eliminate variability with a monographed assay, Thrombosis Research, 30, 337-346, 1983.

Lee ML. Statistical indiscretion, JAMA, 250, 2470, 1983.

Gee LW, Harvey JMGH, Olson WP, and Lee ML. Sterility test systems for product recovery, J. Pharm. Sci., 74, 29-32, 1985.

Ochs H, Fischer S, Virant F, Lee ML, Kingdon HS, Wedgwood R. Hepatitis and intravenous immunoglobulins, Lancet, i, 404-5, 1985.

Gomperts ED, Fannon RB, Lee ML, Kingdon HS, Kantrowitz JL, Addiego JE, Carney J, Corrigan JJ, Hathaway W, Hilgartner MW, Katz J, Lovrien EW. Proplex vs. Proplex SX: A controlled double blind study of the effectiveness in treating acute hemarthroses in

hemophilia A patients with inhibitors to Factor VIII, Thrombosis Research, 42, 789-796, 1986.

Ochs HD, Fischer SH, Virant FS, Lee ML, Mankarious S, Kingdon HS, and Wedgwood R. Non-A non-B hepatitis and intravenous immunoglobulins, Lancet, i, 323, 1986.

Ochs HD, Fischer SH, Lee ML, Delson ES, Kingdon HS, Wedgwood RJ. Intravenous immunoglobulin home treatment for patients with primary immunodeficiency disease, Lancet, i, 610-611, 1986.

Piszkiewicz D, Andrews J, Holst S, Kingdon H, Lee ML, Mankarious S, McDougal, JS, Slimak W, and Hooper J. Safety of immunoglobulin preparation containing antibody to LAV/HTLV-III, Prog. in Immunodeficiency Research and Therapy II, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, 197-200, 1986.

Ochs H, Lee ML, Fischer S, Delson E, Kingdon H, and Wedgwood R. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home, J. Infectious Diseases, 156, 652-654, 1987.

Lee ML, Kingdon HS, Hooper J, Courter SG, Holst SL, and Piszkiewicz D. Safety of an intravenous immunoglobulin preparation: Lack of seroconversion for human immunodeficiency virus antibodies, Clinical Therapeutics, 9, 300-303, 1987.

Piszkiewicz D, Kingdon H, Lee ML, Hooper J. The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products, Develop. Biol. Standard., 67, 327-331, 1987.

Kantrowitz JL, Lee ML, McClure DA, Kingdon HS, and Thomas WR. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to Factor VIII, Clinical Therapeutics, 9, 405-419, 1987.

Ochs HD, Lee ML, Fischer SH, Kingdon HS, and Wedgwood RJ. Efficacy of a new intact intravenous immunoglobulin preparation (Gammagard®) in primary immunodeficient patients, Clinical Therapeutics, 9, 512-522, 1987.

Berkman SA, Lee ML, and Gale RP. Clinical uses of intravenous immunoglobulins, Seminars in Hematology, 25, 140-158, 1988.

Mankarious S, Lee ML, Fischer S, Ochs HD, Wedgwood R. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are

receiving intravenously administered immunoglobulins. J Lab Clin Med, 112, 634-640, 1988.

Lee ML, Courter SG, Tait DA, and Kingdon HS. Long-term evaluation of intravenous immune globulin preparation with regard to non-A, non-B hepatitis safety. In: Zuckerman, A, ed., Viral Hepatitis and Liver Disease, New York: Alan R. Liss, 1988, pg 596-599.

Co-operative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. A randomized controlled clinical trial of intravenous immunoglobulin in chronic lymphocytic leukemia. New Engl. J. Med., 319, 901-907, 1988.

Lee ML, Kantrowitz JL, and Taylor MG. Statistical evaluation of quality control tests. Pharmaceutical Technology, 12, 108-120, 1988.

Griffiths H, Brennan V, Lea J, Bunch C, Lee ML, and Chapel H. Cross-over study of immunoglobulin replacement therapy in patients with low grade B-cell tumors, Blood, 73, 366-368, 1989.

Berkman SA, Lee ML, and Gale RP. Clinical uses of intravenous immunoglobulins. Ann Int. Med., 112, 278-292, 1990.

Lee ML, Poon W-Y, Kingdon HS. A two-phase linear regression model for biological half-life data. J. Lab Clin. Med., 115, 745-748, 1990.

Lee ML, and Kingdon HS. Response to "Assay discrepancies with highly purified Factor VIII concentrates," Thrombosis and Hemostasis, 20, 251-252, 1990.

Gale RP, and Lee ML. Do different therapies of AML produce different outcomes? Leukemia Research, 14, 207-208, 1990.

Barron KS, Murphy DJ, Silverman ED, Ruttenberg HD, Wright GB, Franklin W, Goldberg SJ, Higashino SM, Cox DG, and Lee ML. Treatment of Kawasaki Syndrome: A comparison of two dosage regimens of intravenous immune globulin. J. of Pediatrics, 117, 638-644, 1990.

Dunn OJ, Clark VA, Lee M, and Chon Y. Applied Statistics: Analysis of Variance and Regression, 2nd ed., Answers to exercises. UCLA Department of Biostatistics, 1990.

29. Kingdon HS, Piszkiewicz D, Lee ML, Comter SG, Addiego JE. Hemofil M: Preclinical studies and clinical protocol design. Proceedings of the 6th International Symposium of Hemostasis and Thrombosis, 91-96, 1990.

30. Lee ML, and Lusher JM. The problem of therapeutic equivalence with paired qualitative data: An example from a clinical trial using hemophiliacs with an inhibitor to Factor VIII, Statistics in Medicine, 10, 433-441, 1991.

31. Lee ML, Mankarious S, Ochs H, Fischer S, and Wedgwood RJ. The pharmacokinetics of total IgG, IgG subclasses, and type specific antibodies in immunodeficient patients. Immunol. Investigations, 20, 193-198, 1991.

32. Chapel H, Griffiths H, Brennan V, Bunch C, Lea J, and Lee ML. Hypogammaglobulinemia in low grade B cell tumors: significance and therapy. Immunol. Investigations, 20, 187-191, 1991.

33. Chapel H, Griffiths H, and Lee M. IVIG indication in patients with low-grade B-cell tumors. In: Imbach, P. (Ed.), Immunotherapy with Intravenous Immunoglobulins. London: Academic Press, 165-172, 1991.

34. Morfini M, Lee ML, Messori A, and the Factor VIII/IX Scientific and Standardization Committee of the International Society for Thrombosis and Hemostasis. The design and analysis of half-life and recovery studies for Factor VIII and Factor IX. Thrombosis and Haemostasis, 66, 384-986, 1991.

35. Dicato M, Chapel H, Gamm H, Lee M, Ries F, Marichal S, Wirth C, Griffith H, Brennan V. Use of intravenous immunoglobulin in chronic lymphatic leukemia. A brief review. Cancer, 68, 1437-1439, 1991.

36. Hargreaves RM, Lea JR, Griffiths H, Faux J, Lee M, Chapel HM. Immunological response in myeloma. In: Chapel, H.M., Levinsky, R.J., Webster, A.D.B. (eds). Progress in Immune Deficiency III. London: Royal Society of Medicine Services, 138, 1991.

37. Chapel HM, Lee ML. Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): Kinetics of immunoglobulin metabolism. J. Clin. Immun., 12, 17-20, 1992.

38. Addiego JE, Gomperts E, Liu SL, Bailey P, Courter SG, Lee ML, Neslund GG, Kingdon HS, Griffith MJ. Treatment of hemophilia A with a highly purified Factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thrombosis and Haemostasis, 67, 19-27, 1992.

39. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré Syndrome. New Engl J Med., 326, 1123-1129, 1992.

40. Baker CJ, Melish MB, Hall RT, Casto DT, Vasan V, Givner LB, and the Multicenter Group for the Study of IVIG in Neonates. Intravenous immune globulin for the prevention of nosocomial infection in low birth weight neonates. New Engl J Med., 327, 213-219, 1992.

41. Cometta A, Baumgartner JD, Lee ML, Hanique G, Glauser MP, and the Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. New Engl J Med., 327, 234-240, 1992.

42. Morfini M, Longo G, Messori A, Lee M, White G, Mannucci P, and the Recombinate Study Group. Pharmacokinetic properties of recombinant Factor VIII compared with a monoclonally purified concentrate (Hemofil® M). Thrombosis and Haemostasis, 68, 433-435, 1992.

43. Griffiths H, Lea J, Bunch C, Lee M, Chapel H. Predictors of infection in chronic lymphocytic leukaemia (CLL). J Clin Exp Immunol., 89, 374-377, 1992.

44. Soon-Shiong P, Feldman E, Nelson R, Komtebedde J, Smidsrod O, Skjak-Braek G, Espevik T, Heintz R, and Lee M. Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets. Transplantation, 54, 769-774, 1992.

45. Lee ML, Gomperts ED, and Kingdon, HS. A note on the calculation of recovery for Factor VIII infusions, Thrombosis and Haemostasis, 69, 87, 1993.

46. Strand V, Lee ML, and the CD5 Plus RA Investigators Group. Differential patterns of response in patients with rheumatoid arthritis following administration of an anti-CD5 immunoconjugate. Clin Exp Rheumatol, 11 (Suppl 8), S161-S163, 1993.

47. Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, Olsen NJ, Lee ML, Lorenz TJ, Nelson B, and the CD5 Plus RA Investigators Group. Effects of administration of an anti-CD5 Plus immunoconjugate in rheumatoid arthritis: Results of two phase II studies. Arthritis and Rheumatism, 36, 620-630, 1993.

48. Bray GL, Gomperts ED, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel K, Courter S, Lee M, and the Recombinate Study Group. A multi-center study of recombinant Factor VIII (Recombinate®): Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood, 83, 2428-2435, 1994.

49. Lee ML, and Courter SG. Quality of life assessment versus clinical outcome measures: An example. Drug Information Journal, 28, 39-43, 1994.

1. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG, and the UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Randomized trial of

intravenous immuoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet, 343, 1059-1063, 1994.

51. Levy J, Youvan T, Lee M, and the Passive Hyperimmune Therapy Study Group. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: Results of a 12-month multicenter double blind controlled trial. Blood, 84, 2130-2135, 1994.

52. Chapel H and Lee M. The use of intravenous immune globulin in multiple myeloma. Clin Exp. Immunol, 97 (suppl 1), 21-24, 1994.

53. Thomas DP, Dasani H, Giangrande PLF, Lee CA, Hampton KK, Harman C, Lee ML. A cross-over pharmacokinetic study of prothrombin complex concentrate and a purified Factor IX concentrate. Brit. J. Hemat, 88, 1994.

54. Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, and Lee M. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimens. Brit J. Haematol, 88, 209-212,1994.

55. Busch MP, Operskalski EA, Mosley JW, Stevens CE, Schiff ER, Kleinman SH, Lee H, Lee M, Harris M, and the Transfusion Safety Study Group. Epidemologic background and long-term course of disease in human immunodeficiency virus type 1-infected blood donors identified before routine laboratory screening. Transfusion, 34, 858-864, 1994.

56. Gamm H, Huber CH, Chapel H, Lee M, Ries F, Dicato MA. Intravenous immune globulin in chronic lymphocytic leukaemia. Clin. Exp. Immunol, ­97­ (suppl 1), 17-20, 1994.

57. Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C, Bunch C, Lee M, and Chapel HM. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol, 48, 260-66, 1995.

58. Abzug MJ, Keyserling HL, Lee ML, Levin MJ, Rothbart HA. Neonatal enterovirus infection: Virology, serology, and effects of intravenous immune globulin. Clin Inf Dis, 20, 1201-6, 1995.

59. Harada N, Chiu V, Fowler E, Lee M, Reuben DB. Physical therapy to improve functioning of older people in residential care facilities. Phys Ther, 75, 830-839, 1995.

60. Lee ML, Chapel H, Bennan V, Gamm H, Dicato M, Courter SG. Quality of life assessments and clinical outcome measures in patients with B-cell lymphoproliferative disease receiving intravenous immunoglobulin. In: Proceedings: Early Decision in DMARD Development IV. Biologic Agents in Autoimmune Disease. Atlanta, Ga: Arthritis Foundation, 1995.

61. Strand V, Lee M. Intravenous immunoglobulin (IVIG) in the treatment of autoimmune disease. In: Strand V, Simon L, Scott R (eds.), Emerging Therapies in Autoimmune Disease. New York: Marcel Dekker, 1996, 235-256.

62. Gifford DR, Mittman BS, Fink A, Lanto AB, Lee ML, Vickrey BG. Can a specialty society educate its members to think differently about clinical decisions? Results of a randomized trial. J Gen Intern Med, 11: 664-672, 1996

63. Lee ML. Quality of life and cost-effectiveness issues of IVIG in chronic lymphocytic leukemia: A re-evaluation. In: Kazatchkine MD, Morell A (eds). Intravenous Immunoglobulin Research and Therapy. New York: Parthenon Publishing Group, 1996, 350-351.

64. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton Syndrome. Neurology, 1997.

65. McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R. Use of fibrin sealant in thermal injury. J Burn Care Rehabil, 18: 429-34, 1997.

66. Atkinson JB, Gomperts ED, Kang R, Lee M, Arensman RM, Bartlett RH, Rais-Bharami K,, Breaux CW, Cornish JD, Haase GM, Roden J, Zwischenberger JB. Prospective, randomized evaluation of the efficacy of fibrin sealant as a topical hemostatic agent at the cannulation site in neonates undergoing extracorporeal membrane oxygenation. Am J Surg, 173: 479-484, 1997.

67. White GC, Courter S, Bray GL, Lee M, Gomperts ED and the Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate™) in previously treated patients with hemophilia A. Thrombosis and Haemostasis, 77: 660-7, 1997.

68. Lee ML, Gale RP, Yap PL. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. Ann Rev Med, 48: 93-102, 1997.

69. Lee ML, Strand V. Pharmacoeconomics of intravenous immunoglobulin. In: Lee ML, Strand V (eds.), Intravenous Immunogloblins in Clinical Practice. New York: Marcel Dekker, 1997, 19-22.

70. Lee ML. Alternative methods for the administration of intravenous immunoglobulins. In: Lee ML, Strand V (eds.), Intravenous Immunoglobulins in Clinical Practice. New York: Marcel Dekker, 1997, 107-111.

71. Lee ML. Intravenous immunoglobulin and other autoimmune diseases. In: Lee ML, Strand V (eds.), Intravenous Immunoglobulins in Clinical Practice. New York: Marcel Dekker, 1997, 447-449.

72. Lee ML, Courter SG. Quality of life assessment versus clinical outcome measures. Adv in Thenatology, 8: 39-43, 1997

73. Sorenson PS, Wanscher B, Jensen CV, Schrieber K, Blinkenberg M, Ravnborg M, Kirsmerer H, Laaren VA, Lee ML. Intravenous immune globulin G reduces MRI activity in relapsing multiple sclerosis. Neurology, 50: 1273-1281, 1998.

1. Kerr EA, Hays R, Mitchinson A, Lee M, Siu AL. The influence of gatekeeping and utilization review to control access to specialists on patient satisfaction with care. Medical Care Research and Review, 55: 59-77, 1998.
2. Chernof BA, Sherman SE, Lanto AB, Lee ML, Yano EM, Rubenstein I.V. Health habit counseling amidst competing demands: effects of patient health habits and visit characteristics. Med Care 37: 738-47, 1999.
3. Dresselhaus TR, Luck J, Wright BC, Spragg RG, Lee ML, Bozzette SA. Analyzing the time and value of house staff inpatient work. J Gen Intern Med 13: 534-40, 1998.
4. Greenhalgh DG, Gamelli RL, Lee ML, Delavari M, Lynch JB, Hansbrough JF, Achauer BM, Miller SF, MacPhee M, Bray GL. A multicenter trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the treatment of burn wounds. J. Trauma: Injury, Infection and Critical Care, 46: 433-440, 1999.
5. Rodell MB, Lee ML. Determination of reasons for cessation of participation in serial plasmapheresis programs. Transfusion, 39: 900-903, 1999.
6. Smith BL, Lee M, Leader S, Wertlake P. Economic impact of automated primary screening for cervical cancer. J Reprod Med, 44: 518-528, 1999.
7. Waytes AT, Igel H, Zerlanth G, Wappler N, Lee M, Schwarz O. A safer plasma supply from renumerated donors, “The Immuno/Community Bio-Resources Experiment”. In: Brown F, Vyas G (eds): Advances in Transfusion Safety. Dev. Bio. Basel: Karger, 37-51, 1999.
8. Spertini F, Leimgruber A, Morel B, Khazaeli MB, Yamamoto K, Dayer JM, Weisbart RH, Lee ML. Idiotypic vaccination with a murine anti-ds DNA antibody: Phase I study in patients with non-active systemic lupus erythematosus with nephritis. J Rheumatology, 26: 2602-8, 1999.
9. Shekelle PG, Kravitz RL, Beart J, Marger M, Wang M, Lee M. Are nonspecific guidelines potentially harmful? A randomized comparison of the effect of nonspecific or specific guidelines on physician decision-making. Health Services Research, 34: 1429-1448, 2000.
10. Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson PB, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. A phase I trial of solubilized DR 2: MBP 84-102 (AG284) in multiple sclerosis. Neurology, 54: 1414-1420, 2000.
11. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients and chart abstraction: A prospective validation study of 3 methods for measuring quality. J Amer Med Assoc, 283: 1715-1722, 2000.
12. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res, 10: 81-92, 2000.
13. Saliba D, Kington R, Buchanan J, Bell R, Wang M, Lee M, Herbst M, Lee D, Sur D, Rubenstein L. Appropriateness of the decision to transfer nursing facility residents to the hospital. J Am Geriatr Soc, 48: 154-163, 2000.
14. Parham GP, Andrews NR, Lee ML. Comparison of immediate and deferred colposcopy in a cervical screening program. Obstet Gynecol, 95: 340-4, 2000.
15. Dresselhaus TR, Peabody JW, Lee M, Wang M, Luck J. Measuring compliance with preventive care guidelines: a comparison of standardized patients, clinical vignettes and the medical record. J Gen Int Med, 15: 782-8, 2000.
16. St. Clair EW, Cohen SB, Lee ML, Fleischmann RM, Lee SH, Moreland LW, Olsen NJ, Pratt PW, Yocum DE, Heck L, Winkelhake J, Holcenberg JS, Shulman MJ. Treatment of rheumatoid arthritis with a DR4/1 peptide. J Rheumatol, 27: 1855-63, 2000.
17. Luck J, Peabody JW, Dresslhaus TR, Lee M, Glassman P. How well does chart abstraction measure quality? A prospective comparison of standardized patients with the medical record. Am J Med, 108: 642-649, 2000.
18. Kramer BJ, Damron-Rodriguez J, Lee M, Wang M. Medical house staff performance on the facts of aging quiz: a comparison of test formats. Geron Geriatrics Educ. 21: 41-51, 2001.
19. Ramey DW, Lee M, Messer NT. A review of the Western veterinary literature on equine acupuncture. J Eq Vet Sci 21: 56-60, 2001.
20. Lee M, Morfini M, Schulman S, Ingerslev J, and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors. Website of the International Society for Thrombosis and Haemostasis ([www.isth.org](http://www.isth.org)), 2002.
21. Lee ML, Yano EM, Wang M, Simon BF, Rubenstein LV. What patient population does visit-based sampling in primary care settings represent? Medical Care, 40: 761-770, 2002.
22. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neuro, 9: 557-563, 2002.
23. Korthuis PT, Asch S, Mancewicz M, Shapiro MF, Mathews WC, Cunningham WE, McCutchan JA, Gifford A, Lee ML, Bozzette SA. Measuring medication: Do interviews agree with medical record and pharmacy data? Medical Care, 40: 1270-1282, 2002.
24. Cradock-O’Leary J, Young AS, Yano EM, Wang M, Lee ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv, 53: 874-878, 2002.
25. Hambleton J, Wages D, Radu-Radulescu L, Adams, M, MacKenzie M, Shafer S, Lee M, Smyers J, Wiesehahn G, Corash L. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion, 42: 1302-1307, 2002.
26. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee ML, Storer TW, Casaburi R, Shen R, Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab, 283: E154-E164, 2002.
27. Herndon B, Asch SM, Kilbourne AM, Wang M, Lee M, Wenzel SL, et al. Prevalence and predictors of HIV testing among a probability sample of homeless women in Los Angeles County. Public Health Rep, 118: 261-269, 2003.
28. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, Bhasin S. Development of models to predict anabolic response to testosterone administration in healthy young men. Amer J Physiol Endocrinol Metab, 284: E1009-E1017, 2003.
29. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov J, Casaburi R and Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab, 88: 1478-1485, 2003.
30. Sinha-Hikim I, Roth SM, Lee ML, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab, 285: E197-E205, 2003.
31. Bhasin S, Singh AB, Mac P, Carter B, Lee ML, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan. J Andrology, 24: 299-311, 2003.
32. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A, and the StreptIg Study Group (includes M Lee). Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Inf Dis, 37: 333-340, 2003.
33. Lee ML, Morfini M. Controversial use of meta-analysis for factor VIII pharmacokinetic data. Haemophilia, 9: 746-747, 2003.
34. Huang PY, Yano EM, Lee ML, Chang BL, Rubenstein LV. Variation in nurse practitioner use in Veterans Affairs primary care practices. Health Services Research, 39: 887-904, 2004.
35. Damron-Rodriguez J, Funderburk B, Lee M, Solomon, D. Undergraduate knowledge of aging: A comparative study of biopsychosocial content. Geron Geriatrics Educ, 25: 53-71, 2004.
36. Le T, Cherry JD, Chang S-J, Knoll MD, Lee ML, Barenkamp S, Bernstein D, Edelman R, Edwards KM, Greenberg D, Keitel W, Treanor J, Ward JI. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: The APERT Study. J Inf Dis, 190: 535-544, 2004.
37. Korthuis PT, Asch SM, Anaya HD, Morgenstern H, Goetz MB, Yano EM, Rubenstein LV, Lee ML, Bozzette SA. Lipid-screening in HIV-infected veterans. J Acquir Immune Defic Syndr, 35: 253-260, 2004.
38. Visser LH, Beekman R, Tijssen CC, Uitdehaag BMJ, Lee ML, Movig KLL, Lenderink AW. A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS. Multiple Sclerosis, 10: 89-91, 2004.
39. Peabody JW, Luck J, Glassman P, Jain S, Hansen J, Spell M, Lee M. Measuring the quality of physician practice by using clinical vignettes: A prospective validation study. Ann Intern Med 141: 771-780, 2004.
40. Cheng EM, Siderowf A, Swarztrauber K, Eisa M, Lee, M, Vickrey BG. Development of quality of care indicators for Parkinson’s disease. Movement Disorders, 19: 136-150, 2004.
41. Beekman R, Wokke JH, Schoemaker MC, Lee ML, Visser LH. Ulnar neuropathy at the elbow: Follow-up and prognostic factors determining outcome. Neurology, 63: 1675-80, 2004.
42. Chiou C-F, Sherbourne CD, Ofman J, Lee M, Lubeck DP, Paulus HE, Weisman M. Development and validation of Cedars-Sinai Rheumatoid Arthritis Health-Related Quality of Life (CSHQ-RA) short-form instrument. Arthritis and Rheumatism, 51: 358-64, 2004.
43. Cherry JD, Chang SJ, Klein D, Lee M, Barenkamp S, Bernstein D, Edelstein R, Decker MD, Greenberg DP, Keitel W, Treanor J, Ward JI. Prevalence of antibody to Bordella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis 39: 1715-1718, 2004.
44. Lee ML, Roth DR. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia, 11: 5-12, 2005.
45. Choi HH, Gray PB, Storr TW, Calof OM, Woodhouse L, Singh AB, Padero C, Mac RP, Sinha-Hikim I, Shen R, Dzekov J, Dzekov C, Kushnir MM, Rockwood AL, Meikle AW, Lee ML, Hays RD, Bhasin S. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. J Clin Endo Metab 90: 1531-1541, 2005.
46. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60: 1451-7, 2005.
47. Hawthorne WB, Green EE, Gilmer T, Garcia P, Hough RL, Lee M, Hammond L, Lohr JB. A randomized trial of short-term acute residential treatment for veterans. Psychiatr Serv 56: 1379-1386, 2005.
48. Sundberg-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33: 564-573, 2005.
49. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheki KE, Sinha-Hakim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90: 678-688, 2005.
50. Jasuja R, Ramaraj P, Mac RP, Singh AB, Storer TW, Artaza J, Miller A, Singh R, Taylor WE, Lee, ML, Davidson T, Sinha-Hikim I, Gonzalez-Cadavid N, Bhasin S. Δ-4-andosten-3,17-dione binds androgen receptor, promotes myogenesis in vitro and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men. J Clin Endocrinol Metab 90: 855-863, 2005.
51. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 45: 1362-1372, 2005.
52. Lee ML. The design and analysis of studies in premature infants using human donor milk or preterm formula as primary nutrition: A critique of Schanler et al. Breastfeeding Medicine, 1: 88-93, 2006.
53. Glanz JM, McClure DL, Xu S, Hambridge SJ, Lee M, Kolczak MS, Kleinman K, Mullooly JP, France EK. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiology, 59: 808-818, 2006.
54. Chin PS, Berg AT, Spencer SS, Lee ML, Shinnar S, Sperling MR, Langfitt JT, Walczak TS, Pacia SV, Bazil CW, Vassar S, Vickrey BG. Patient-perceived impact of resective epilepsy surgery. Neurology, 66: 1882-1887, 2006.
55. Lee M, Morfini M, Negrier C, Chamouard V. The pharmacokinetics of coagulation factors. Haemophilia 12 (suppl. 3): 1-7, 2006.
56. Singh AB, Lee ML, Sinha-Hikim I, Kushnir M, Meikle W, Rockwood A, Afework S, Bhasin S. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J Clin Endocrinol Metab 91: 136-144, 2006.
57. Rechtman DJ, Lee ML, Berg H. Effect of environmental conditions on unpasteurized donor human milk. Breastfeeding Medicine, 1: 24-26, 2006.
58. Glassman PA, Belperio P, Simon B, Lanto A, Lee M. Exposure to automated drug alerts over time: Effects on clinicians’ knowledge and perceptions. Med Care 44: 250-256, 2006.
59. Seelig M, Gelberg L, Tavrow P, Lee M, Rubenstein L. Determinants of physician unwillingness to offer medical abortion using mifepristone. Women’s Health Issues 16: 14-21, 2006.
60. Chodosh J, Berry E, Lee M, Connor K, DeMonte R, Ganiats T, Heikoff L, Rubenstein L. Mittman B, Vickrey B. Effect of dementia care management intervention on primary care provider knowledge, attitudes, and perceptions of quality of care. J Am Geriatr Soc 54: 311-317, 2006.
61. Cope JR, Yano ER, Lee ML, Washington DL. Determinants of contraceptive availability at medical facilities in the Department of Veterans Affairs. J. Gen Int Med 44: 398-405, 2006.
62. Etzioni DA, Yano EM, Rubenstein LV, Lee ML, Ko CY, Brook RH, Parkerton PH, Asch SM. Measuring the quality of colorectal cancer screening: the importance of follow-up. Diseases of the Colon and Rectum 49: 1002-1010, 2006.
63. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indices for symptoms of atherosclerotic disease. Am J Cardiology 96: 1047-1052, 2006.
64. Vickrey BG, Mittman BS, Connor KI, Pearson ML, Della Penna RD, Ganiats TG, DeMonte RW, Chodosh J, Cui X, Vassar S, Duan N, Lee M. The effect of a disease management intervention on quality and outcomes of dementia care. Ann Int Med 145: 713-726, 2006.
65. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2: 146-159, 2006.
66. Rubenstein LV, Meredith LS, Parker LE, Gordon NP, Hickey SC, Oken C, Lee ML. Impacts of evidence-based quality improvement on depression in primary care: a randomized experiment. J Gen Intern Med 21: 1027-1035, 2006.
67. Cheng EM, Swarztrauber K, Siderowf AD, Eisa MS, Lee M, Vassar S, Jacob E, Vickrey BG. Association of specialist involvement and quality of care for Parkinson’s Disease. Movement Disorders 22: 515-522, 2007.
68. Terpstra FG, Rechtman DJ, Lee ML, Van Hoeij K, Berg H, Van Engelenberg FAC, Van’t Wout AB. Antimicrobial and antiviral effect of high-temperature short-term (HTST) pasteurization applied to human milk. Breastfeeding Medicine 2: 27-33, 2007.
69. Chodosh J, Mittman BS, Connor KI, Vassar SD, Lee ML, DeMonte RW, Ganiats TG, Heikoff LE, Rubenstein LZ, Della Penna RD, Vickrey BG. Caring for patients with dementia: How good is the quality of care? Results from three health systems. J Am Geriatr Soc 55: 1260-1268, 2007.
70. Chodosh J, Sultzer DL, Lee ML, Hahn TJ, Reuben DB, Yano EM, Mittman BS, Rubenstein LZ. Memory impairment among primary care veterans. Aging & Mental Health 11: 444-450, 2007.
71. Glassman PA, Belperio P, Lanto A, Simon B, Valuck R, Sayers J, Lee M. The utility of adding retrospective medication profiling to computerized provider order entry in an ambulatory care population. J Am Med Inform Assoc 14: 424-431, 2007.
72. Sunden-Cullberg J, Nystrom T, Lee ML, Mullins GE, Tokics L, Andersson J, Norrby-Teglund A, Treutiger CJ. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 35: 1536-1542, 2007.
73. Meyer CU, Zepp F, Decker M, Lee M, Chang S-J, Ward J, Yoder S, Bogaert H, Edwards KM. Cellular immunity in adolescents and adults given acellular pertussis (dTap) vaccine. Clin Vaccine Immunol 14: 288-292, 2007.
74. Chan GM, Lee ML, Rechtman DJ. Effects of a human milk-derived human milk fortifier on the antibacterial actions of human milk. Breastfeeding Medicine 2: 205-208, 2007.
75. Visser LH, Smidt MH, Lee ML. High-resolution sonography versus EMG in the diagnosis of carpal tunnel syndrome. J Neurol Neurosurg Psychiatry 79: 63-67, 2008.
76. Singhal R, Rubenstein LV, Wang M, Lee M, Felix JC, Raza A, Holschneider CH. Variations in practice guideline adherence for abnormal cervical cancer cytology follow-up in a county healthcare system. J Gen Intern Med 23: 575-580, 2008.
77. Connor KI, McNeese-Smith DK, Vickrey BG, van Servellen GM, Chang BL, Lee ML, Vassar SD, Chodosh J. Determining care management activities associated with mastery and relationship strain for dementia caregivers. J Am Geriatr Soc 56: 891-897, 2008.
78. Yano EM, Rubenstein LV, Farmer, MM, Chernof BA, Mittman BS, Lanto AB, Simon BF, Lee ML, Sherman SE. Targeting primary care referrals to smoking cessation clinics does not improve quit rates: The difficulty of translating evidence-based interventions into everyday practice. Health Services Research 43: 1485, 2008.
79. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieshi C, Thon V, Abedi MR, Hammarstrom L. Common variable immunodeficiency disorders: Division into distinct clinical phenotypes. Blood, 112: 277-86, 2008.
80. Visser LH, Smidt MH, Lee ML. Diagnostic value of wrist median nerve cross sectional area versus wrist-to-forearm ratio in carpal tunnel syndrome. Clin Neurophysiol 119: 2898-9, 2008.
81. Pall ME, Lao MC, Patel SS, Lee ML, Ghods DE, Chandler DW, Friedman TC. Testosterone and bioavailable testosterone help to distinguish between mild Cushing’s syndrome and polycystic ovarian syndrome. Horm Metab Res 40: 813-8, 2008.
82. Zangwill KM, Eriksen E, Lee M, Lee J, Marcy SM, Friedland LR, Weston W, Howe B, Ward JI. A population-based, post-licensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. Pediatrics 122: 1179-85, 2008.
83. Wojcik KY, Rechtman DJ, Lee ML, Montoya A, Medo ET. Macronutrient analysis of a nationwide sample of donor breast milk. J Am Diet Assoc 109: 137-40, 2009.
84. Kramer, BJ, Wang M, Jouldjian S, Lee ML, Finke B, Saliba D. Veterans Health Administration and Indian Health Service: Healthcare utilization by Indian Health Service enrollees. Medical Care 47: 670–676, 2009.
85. [Batra JS](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Batra%20JS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Eriksen EM](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Eriksen%20EM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Zangwill KM](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zangwill%20KM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Lee M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lee%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Marcy SM](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Marcy%20SM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Ward JI](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ward%20JI%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract). Evaluation of vaccine coverage for low birth weight infants during the first year of life in a large managed care population. Pediatrics 123: 951-958, 2009.
86. Lee ML. The use of animal pharmacokinetic data to evaluate human dosing. Haemophilia 16: 508-9, 2009.
87. Connor K, McNeese-Smith D, van Servellen G, Chang B, Lee M, Cheng E, Hajar A, Vickrey BG. Insight into dementia care management using social-behavioral theory and mixed methods. Nurs Res 58: 348-58, 2009.
88. Sullivan S, Schanler RJ, Kim JH, Patel AL, Trawoger R, Kiechl-Kohlendorfer U, Chan GM, Blanco CL, Abrams S, Cotton CM, Laroia N, Ehrenkranz RA, Dudell G, Cristafalo EA, Meier P, Lee ML, Rechtman DJ, Lucas A. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. J Pediatrics 156: 562-7, 2010.
89. Wohl AR, Galvan F, Myers HF, Garland W, George S, Witt M, Cadden J, Operskalski E, Jordan W, Carpio F, Lee ML. Do social support, stress, disclosure and stigma influence retention in HIV care for Latino and African American men who have sex with men and women? AIDS Behav (published online, 2010)
90. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125: 1354-60, 2010.
91. Cheng EM, Cohen SN, Lee ML, Vassar SD, Chen AY. Use of antithrombotic agents among U.S. stroke survivors, 2000-2006. Am J Prev Med 38: 47-53, 2010.
92. Friedman TC, Ghods DE, Shahinian HK, Zachery L, Shayesteh N, Seasholtz S, Zuckerbraun E, Lee ML, McCutcheon IE. High prevalence of normal tests assessing hypercortisolism in subjects with mild and episodic Cushing’s syndrome suggests that the paradigm for diagnosis and exclusion of Cushing’s syndrome requires multiple testing. Horm Metab Res 42: 874-81, 2010.
93. Shugarman LR, Goebel JR, Lanto A, Asch SM, Sherbourne CD, Lee ML, Rubenstein LV, Wen, L, Meredith L, Lorenz KA. Nursing staff, patient, and environmental factors associated with accurate pain assessment. J Pain Symptom Manage 40: 723-33, 2010.
94. Washington DL, Yano EM, McGuire J, Hines V, Lee M, Gelberg L. Risk factors for homelessness among women veterans. J Health Care Poor Underserved 21: 82-91, 2010.
95. Zangwill KM, Yeh SH, Wong EJ, Marcy SM, Eriksen E, Huff KR, Lee M, Lewis EM, Black SB, Ward JI. Paralytic syndrome in children: epidemiology and relationship to vaccination. Pediatr Neurol 42: 206-12, 2010.
96. Noori N, Kovesdy CP, Bross R, Lee M, Oreopoulos A, Benner D, Mehrotra R, Kopple JD, Kalantar-Zadeh K. Novel equations to estimate lean body mass in maintenance hemodialysis patients. Am J Kidney Dis 57: 130-9, 2011.
97. Wohl AR, Galvan FH, Myers HF, Garland W, George S, Witt M, Cadden J, Operskalski E, Jordan W, Carpio F, Lee ML. [Do social support, stress, disclosure and stigma influence retention in HIV care for Latino and African American men who have sex with men and women?](http://www.ncbi.nlm.nih.gov/pubmed/20963630) AIDS Behav 15: 1098-1110, 2011.
98. Martinowitz U, Shapiro A, Quon D, Escobar M, Kempton C, Collins P, Chowdary P, Makris M, Mannucci P, Morfini M, Valentino L, Gomperts E, Lee M. Pharmacokinetics of IB1001, a new recombinant factor IX. Haemophilia 17: 27-30, 2011.
99. Davidson MB, Tareen N, Duran P, Aguilar V, Lee ML. [Aggressive versus low dose inhibition of the renin-angiotensin system for the treatment of microalbuminuria in type 2 diabetic patients: A pilot study.](http://www.ncbi.nlm.nih.gov/pubmed/22363885) ISRN Endocrinol Epub, 2011.
100. Chaney EF, Rubenstein LV, Liu CF, Yano EM, Bolkan C, Lee M, Simon B, Lanto A, Felker B, Uman J. Implementing collaborative care for depression treatment in primary care: a cluster randomized evaluation of a quality improvement practice redesign. Implement Sci 6: 121, 2011.
101. Shah R, Chen C, O’Rourke S, Lee M, Mohanty SA, Abraham J. Evaluation of care management for the uninsured. Med Care 49: 166-171, 2011.
102. Spina JR, Glassman PA, Simon B, Lanto A, Lee M, Cunningham F, Good CB. Potential safety gaps in order entry and automated drug alerts: a nationwide survey of VA physician self-reported practices with computerized order entry. Med Care 49: 904-10, 2011.
103. Toscos TR, Ponder SW, Anderson BJ, Davidson MB, Lee ML, Montemayor-Gonzalez E, Reyes P, Link E, McMahon KL. [Integrating an Automated Diabetes Management System into the family management of children with type 1 diabetes: results from a 12-month randomized controlled technology trial.](http://www.ncbi.nlm.nih.gov/pubmed/22301127) Diabetes Care 35: 498-502, 2012.
104. Mangubat M, Lutfy K, Lee ML, Pulido L, Stout D, Davis R, Shin CS, Shahbazian M, Seasholtz S, Sinha-Hikim A, Sinha-Hikim I, O'Dell LE, Lyzlov A, Liu Y, Friedman TC.

[Effect of nicotine on body composition in mice.](http://www.ncbi.nlm.nih.gov/pubmed/22138237) J Endocrinol 212:317-26, 2012.

1. Ghandehari H, Lee ML, Rechtman D. [An exclusive human milk-based diet in extremely premature infants reduces the probability of remaining on total parenteral nutrition: A reanalysis of the data.](http://www.ncbi.nlm.nih.gov/pubmed/22534258) BMC Res Notes 5: 188-191, 2012.
2. Chodosh J, Pearson ML, Connor KI, Vassar SD, Kaisey M, Lee ML, Vickrey BG. [A dementia care management intervention: which components improve quality?](http://www.ncbi.nlm.nih.gov/pubmed/22435836) Am J Manag Care 18: 85-94, 2012.
3. Bateman EA, Ayers L, Sadler R, Lucas M, Roberts C, Woods A, Packwood K, Burden J, Harrison D, Kaenzig N, Lee M, Chapel HM, Ferry BL. [T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections.](http://www.ncbi.nlm.nih.gov/pubmed/23039891) Clin Exp Immunol 170: 202-211, 2012.
4. Wojtczak HA, Wachter AM, Lee M, Burns L, Yusin JS. [Understanding the relationship among pharmacoadherence measures, asthma control test scores, and office-based spirometry.](http://www.ncbi.nlm.nih.gov/pubmed/22840250) Ann Asthma Allergy Immunol 109: 103-107, 2012.
5. Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, Gerard L, Oksenhendler E. [Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts.](http://www.ncbi.nlm.nih.gov/pubmed/22819511) J Allergy Clin Immunol, 130: 1197-1198, 2012.
6. Martinowitz U, Shapiro A, Quon DV, Escobar M, Kempton C, Collins PW, Chowdary P, Makris M, Mannucci PM, Morfini M, Valentino LA, Gomperts E, Lee M. [Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.](http://www.ncbi.nlm.nih.gov/pubmed/22764744) Haemophilia, 18: 881-887, 2012.
7. Davidson MB, Duran P, Lee ML, Friedman TC. High dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 36: 260-266, 2013.
8. Gouilleux-Gruart V, Chapel HM, Chevre, S, Lucas M, Malphettes M, Fieschi, C, Patel S, Boutboul D, Marson M-N, Gérard L, Lee M, Watier H, Oksenhendler E. Efficiency of IgG replacement therapy in common variable immunodeficiency: Correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol, 171: 186-194, 2013.
9. Chang ET, Rose DE, Yano EM, Wells KB, Metzger ME, Post EP, Lee ML, Rubenstein LV. Determinants of readiness for Primary Care-Mental Health Integration (PC-MHI) in the VA Health Care System. J Gen Int Med 28:353-362, 2013.
10. Ren X, Lutfy K, Mangubat M, Ferrini MG, Lee ML, Liu Y, Friedman TC. Alterations in phosphorylated CREB expression in different brain regions following short- and long-term morphine exposure: relationship to food intake. J Obesity, article ID 764742, <http://dx.doi.org/10.1155/2013/764742>, 2013
11. Ganapathy V, Hay JW, Kim JH, Lee ML, Rechtman DJ. Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatrics 13:127, 2013.
12. Harawa NT, Williams JK, McCuller WJ, Ramamurthi HC, Lee M, Shapiro MF, Norris

KC, Cunningham WC. Efficacy of a culturally congruent HIV risk reduction

intervention for behaviorally bisexual black men: results of a randomized trial. AIDS 27:

1979-1988, 2013.

1. Cristofalo EA, Schanler RJ, Blanco CL, Sullivan S, Trawoeger R, Kiechl-Kohlendorfer U, Dudell G, Rechtman DJ, Lee ML, Lucas A, Abrams S. Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. J Pediatrics, doi: 10.1016/j.jpeds.2013.07.011, 2013.
2. [Robinson PL](http://www.ncbi.nlm.nih.gov/pubmed?term=Robinson%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=23395954), [Dominguez F](http://www.ncbi.nlm.nih.gov/pubmed?term=Dominguez%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23395954), [Teklehaimanot S](http://www.ncbi.nlm.nih.gov/pubmed?term=Teklehaimanot%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23395954), [Lee M](http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23395954)**,** [Brown A](http://www.ncbi.nlm.nih.gov/pubmed?term=Brown%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23395954), [Goodchild M](http://www.ncbi.nlm.nih.gov/pubmed?term=Goodchild%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23395954), [Hood DB](http://www.ncbi.nlm.nih.gov/pubmed?term=Hood%20DB%5BAuthor%5D&cauthor=true&cauthor_uid=23395954). Does distance decay modeling of supermarket accessibility predict fruit and vegetable intake by individuals in a large metropolitan area? J Health Care Poor Underserved: 24(1 Suppl):172-85, 2013.
3. Rattanasompattikul M, Molnar MZ, Lee ML, Dukkipati R, Bross R, Jing J, Kim Y, Voss AC, Benner D, Feroze U, Macdougall IC, Tayek JA, Norris KC, Kopple JD, Unruh M, Kovesdy CP, Kalantar-Zadeh K. [Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial.](http://www.ncbi.nlm.nih.gov/pubmed/24052226) J Cachexia Sarcopenia Muscle. E-pub 20 SEP 13.
4. Walling AM, Tisnado D, Asch SM, Malin JM, Pantoja P, Dy SM, Ettner SL, Zisser AP, Schreibeis-Baum H, Lee M, Lorenz KA. [The quality of supportive cancer care in the Veterans Affairs Health System and targets for improvement.](http://www.ncbi.nlm.nih.gov/pubmed/24126685) JAMA Intern Med. 2013 Oct 14. doi: 10.1001/jamainternmed.**2013**.10797.
5. Roberts C, Chen BH, Pruthi S, Lee M. Effects of varying doses of testosterone on atherogenic markers in healthy younger and older men. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 4 December 2013 Vol. no. DOI**:** 10.1152/ajpregu.00372.2013.
6. Scheuner MT, Marshall N, Lanto A, Hamilton AB, Oishi, S, Lerner B, Lee, M, Yano EM. Delivery of clinical genetic consultative services in the Veterans Health Administration. Genetics in Medicine. Doi:10.1038/gim.2013.202.
7. Hsia SH, Desnoyers ML, Lee ML. [Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States.](http://www.ncbi.nlm.nih.gov/pubmed/24314367) J Clin Lipidol 7: 675-82, 2013.
8. Noar M, Squires P, Noar E, Lee M. Long-term maintenance of radiofrequency energy delivery of refractory GERD: a decade later. Surg Endosc, 28: 2323-2333, 2014.
9. Davidson MB, Duran P, Lee ML. Community screening for pre-diabetes and diabetes using HbA1c levels in high risk African Americans and Latinos. Ethnicity and Disease, 24: 195-199, 2014.
10. Hytopoulos E, Lee ML, Beggs M, French C, Tong KB. Cost-effectiveness analysis of a next generation risk assessment score for cardiovascular disease. J Med Econ 17: 132-141, 2014.
11. Lozier J, Nghiem K, Lee M, Hodsdon B, Joe G, Weitzel R, Tisdale J; Hsieh M. Acquired hemophilia A after stem cell transplant for sickle cell disease: Treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone. Haemophilia, 2014 e185-8. DOI: 10.1111/hae.12372.
12. Subhash SS, Cavaiuolo M, Radonovich LJ, Eagan A, Lee ML, Campbell S, Martinello RA. Effectiveness of common disinfectants against H1N1 influenza virus on reusable elastomeric respirators. Infection Control and Hospital Epidemiology 35: 894-897, 2014.
13. Abrams SA, Schanler RJ, Lee ML, Rechtman DJ and the Prolacta Study Group. Greater mortality and morbidity in extreme premature infants fed a diet containing cow milk protein products. Breastfeeding Medicine 9: 281-285, 2014.
14. Sinha-Hikim I, Duran P, Shen R, Lee M, Friedman TC, Davidson MB. Effect of long-term vitamin D supplementation on biomarkers of inflammation in Latino and African American subjects with pre-diabetes and hypovitaminosis D. Horm Metab Res, 2014. DOI 10.1055/s-0034-1383652.
15. Hair AB, Blanco CL, Moreira AG, Hawthorne KM, Lee ML, Rechtman DR, Abrams SA. Randomized trial of human milk cream as a supplement to standard fortification of an exclusive human milk-fed diet in infants 750-1250 g BW. J Pediatrics, 2014. DOI 10.1016/j.jpeds.2014.07.005.
16. Lee JXU, Wojtczak HA, Wachter AM, Lee ML, Burns L, Chen D, Yusin JS. Understanding asthma medical nonadherence in adult and pediatric population. J Allergy Clin Imm: In Practice. DOI: <http://dx.doi.org/10.1016/j.jaip.2014.11.022>.
17. Negrier C, Oldenberg J, Potzsch B, Bordet J-C, Al Dieri R, Dargaud Y, Hemker HC, Lee M, Turecek P. Recombinant porcine sequence FVIII corrects thrombin generation and improves clot structure in plasma from hemophilia A patients with inhibitors. Amer J Haematol 89: E44-45, 2014.
18. Scheuner MT, Hamilton AB, Peredo J, Sale TJ, Austin C, Gilman SC, Bowen MS, Goldzweig CL, Lee M, Mittman BS, Yano EM. A cancer genetics toolkit improves access to genetic services through documentation and use of the family history by primary-care clinicians. Genet Med 16: 60-69, 2014.
19. Hodkinson J, Lucas M, Lee M, Harrison M, Lunn M, Chapel H. Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. Clin Exp Immunol, 2015. DOI: 10.111/cei.12616.
20. Mojtahedzadeh M, Lee ML, Friedman TC. Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population. J Diabetes Complications, 2015. DOI: 10.1016/jdiacomp.2015.06.013.
21. Lucas M, Lee M, Oksenhendler E, Chapel H. The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies. J Allergy Clin Immunol Pract 3: 998-1000, 2015.
22. Refaai MA, Goldstein JN, Lee ML, Durn BL, Milling TJ Jr, Sarode R. Increased risk of volume overload with plasma compared to four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion, 2015. DOI: 10.1111/trf.13191.
23. Milling TJ Jr, Refaai MA, Goldstein JN, Schneider A, Omert L, Harman A, Lee ML, Sarode R. Thromboembolic events after vitamin K antagonist reversal with a 4-factor prothrombin complex concentrate: Exploratory analyses of two randomized plasma-controlled trials. Ann Emerg Med, 2015. DOI: 10.1016/j.annemergmed 2015.04.036.
24. Lee ML, Clymer R, Peters K. A naturalistic patient matching algorithm: Derivation and validation. Health Informatics J. DOI: 10.1177/1460458215607080, 2015.
25. Connor K, Cheng E, Siebens HC, Lee M, Mittman BS, Ganz DA, Vickrey B. “CHAPS”:

A randomized controlled trial protocol for of Care Coordination for Health Promotion and Activities in Parkinson’s Disease to improve the quality of care for individuals with Parkinson’s Disease. BMC Neurology 15: 258, 2015.

1. Milling TJ, Refaai MA, Sarode R, Lewis B, Mangione A, Durn BL, Harman A,Lee ML, Goldstein JN. Safety of a 4-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two Phase IIIb clinical trials.

Acad Emerg Med 23: 466-75, 2015.

1. Hair AB, Peluso AM, Hawthorne KM, Perez J, Smith DP, Khan JY, O'Donnell A, Powers RJ, Lee ML, Abrams SA. Beyond necrotizing enterocolitis prevention: Improving outcomes with an exclusive human milk-based diet. Breastfeeding Med 11: 70-74. <https://doi.org/10.1089/bfm.2015.0134>
2. Farmer MM, Rubenstein LV, Sherbourne CD, Huynh A, Chu K, Lam CA, Fickel JJ, Lee

ML, Metzger ME, Verchinina L, Post EP, Chaney EF. Depression quality of care:

Measuring quality over time using VA electronic medical record data. J Gen Int Med.

DOI: 10.1007/s11606-015-3563-4, 2016.

1. Lerner B, Marshall N, Oishi S, Lanto A, Lee M, Hamilton AB Yano EM, Scheuner MT.

The value of genetic testing beyond clinical utility. Genetics in Medicine. DOI: 10.1038/gim.2016.186, 2016.

1. Hair AB, Bergner EM, Lee ML, Moreira AG, Hawthorne KM, Rechtman DJ,

Abrams SA, Blanco CL. Premature infants 750-1250 g birth weight supplemented with

a novel human milk-derived cream are discharged sooner. Breastfeeding Med 11: 133-7, 2016.

1. Rhee CM, You AS, Parsons TK, Tortorici AR, Bross R, St.-Jules DE, Jing J, Lee ML,

Benner D, Kovesdy CP, Mehrotra R, Kopple JD, Kalantar-Zadeh K. Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: Findings from the FrEDI randomized clinical trial. Nephrology Dialysis Transplantation. DOI: 10.1093/ndt/gfw323, 2016.

1. Huynh AK, Lee ML, Farmer MM, Rubenstein LV. Application of a non-randomized

stepped wedge design to evaluate an evidence-based quality improvement intervention:

a proof of concept using simulated data on patient-centered medical homes. BMC Med Res Method. DOI: 10.1 186/s 12874-016-0244-x, 2016.

1. Walling AM, Tisnado D, Ettner SL, Asch SM, Dy SM, Pantoja P, Lee M, Ahluwalia SC,

Schreibeis-Baum H, Malin JL, Lorenz KA. Palliative care specialist consultation is associated with supportive care quality in advanced cancer. Journal of Pain and Symptom Management 52: 507-514, 2016.

1. Hammond HK, Penny WF, Traverse JH, Henry TD, Watkins MW, Yancy CW, Sweis

RN, Adler ED, Patel AN, Murray DR, Ross RS, Bhargava V, Maisel A, Barnard DD, Lai NC, Dalton, ND, Lee ML, Naranyan SM, Blanchard DG, Gao MH. Intracoronary gene transfer of adenyl cyclase 6 in patients with heart failure: A randomized clinical trial JAMA Cardiol. DOI: 10.1001/jamacardio.2016.0008, 2016

1. Scheuner MT, Peredo J, Tangney K, Schoeff D, Sale T, Lubick-Goldzweig C, Hamilton

A, Hilborne L, Lee M, Mittman B, Yano EM, Lubin IM. Electronic health record interventions at the point of care improve documentation of care processes and decrease orders for genetic tests commonly ordered by nongeneticists. Genetics in Medicine 19: 112-120, 2017.

1. Lam CA, Sherbourne C, Gelberg L, Lee ML, Huynh AK, Chu K, Strauss JL, Metzger

ME, Post EP, Rubenstein LV, Farmer MM. Differences in depression care for men and women among veterans with and without psychiatric comorbidities. Women’s Health Issues 27: 206-213, 2017.

1. Davis JA, Tsui I, Gelberg L, Gabrielian S, Lee ML, Chang ET. Risk factors for diabetic

neuropathy among homeless veterans. Psychological Services 14: 221-228, 2017.

1. Refaai M, Kothari T, Straub S, Falcon J, Sarode R, Goldstein JN, Brainsky A, Omert L, Lee ML, Milling T. 4-factor prothrombin complex concentrate reduces time to procedure in vitamin K antagonist-treated patients experiencing gastrointestinal bleeding: a post hoc analysis of two randomized controlled trials. Emerg Med Intl. DOI.org/10.1155/2017/8024356, 2017.
2. Davidson MB, Duran P, Davidson J, Lee M. Comparison of insulin dose adjustments by primary care physicians and endocrinologists. Clinical Diabetes 36: 39-43, 2018.
3. [Chang](https://www.sciencedirect.com/science/article/pii/S1551714418300806) ET**,** Zulman DM, Asch SM, Stockdale SE, Yoon J, Ong MK, Lee M, Simon A, Atkins D, Schectman G, Kirsh SR, Rubenstein LV on behalf of the PIM Executive Committee and Demonstration Sites. “An operations-partnered evaluation of care redesign for high-risk patients in the Veterans Health Administration (VHA): Study protocol for the PACT Intensive Management (PIM) randomized quality improvement evaluation.” Contemporary Clinical Trials 69: 65-75, 2018. <https://doi.org/10.1016/j.cct.2018.04.008>
4. Mojitahedzadeh M, Shaesteh N, Haykani M, Tran JLA, Mangubat M, Shahiman HK, Nachnani R, Zopey M, Saidian J, Thomas A, Lee ML, McCutcheon IE, Friedman TC. Low dose and standard overnight and low dose-two day dexamethasone suppression tests in patients with mild and/or episodic hypercorticolism. Horm Metab Res, 2018. DOI <https://doi.org/10.1055/a-0603-3868>.
5. Hair AB, Rechtman DJ, Lee ML, Niklas V. Beyond necrotizing enterocolitis: Other clinical advantages of an exclusive human milk diet. Breastfeeding Medicine, 2018. DOI: 10.1089/bfm.2017.0192.
6. Rosenson RS, Chen Q, Najera SD, Lee ML, Cho DJ. Ticagrelor and the prevention of microvascular complications in diabetes patients with lower extremity arterial disease; Rationale and design of the Hema-Kinesis Trial. Cardiovascular Drugs and Therapy, 2018. DOI: 10.1007/s10557-018-6815-9.
7. Ganz DA, Barnard JM, Smith NZY, Miake-Lye IM, Delevan DM, Simon A, Rose DE, Stockdale SE, Chang ET, Noël PH, Finley EP, Lee ML, Zulman DM, Cordasco KM, Rubenstein LV. [Development of a web-based toolkit to support improvement of care coordination in primary care.](https://www.ncbi.nlm.nih.gov/pubmed/29800397) Transl Behav Med 8:492-502, 2018. DOI: 10.1093/tbm/ibx072.
8. Radonovich LJ, Wizner K, LaVela SL, Lee ML, Findley K, Yorio P. A tolerability assessment of new respiratory devices developed for healthcare personnel: A randomized simulated clinical study. PLoS ONE 14: e0209559, 2019. DOI.org/10.1371/journal.pone.0209559.
9. Connor KI, Cheng EM, Barry F, Siebens HC, Lee ML, Ganz DA, Mittman BS, Connor MK, Edwards LK, McGowan MG, Vickrey BG. Randomized trial of care management to improve Parkinson disease care quality. Neurology. 2019 Mar 22. pii: 10.1212/WNL.0000000000007324. doi: 10.1212/WNL.0000000000007324.
10. Khandelwal P, Andersen H, Romick-Rosendale L, Taggart CB, Watanabe M, Lane A, Dandoy CE, Lake KE, Litts BA, Morrow AL, Lee ML, Haslam DB, Davies SM. A pilot study of human milk to reduce intestinal inflammation after bone marrow transplant. Breastfeed Med. 2019 Mar 27. doi: 10.1089/bfm.2018.0199.
11. Rosenson R, Chen Q, Najera B, Krishnan P, Lee ML, Cho DJ. Ticagrelor improves blood

viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: The Hema-kinesis Clinical Trial. Cardiovasc Drugs Ther. 2019 Oct;32(5):443-451. doi: 10.1007/s10557-018-6815-9.

237. Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. Journal of Diabetes. 2019;1–4. <https://doi.org/10.1111/1753-0407.12989>.

1. Huston RK, Lee ML, Rider ED, Stawarz ML, Hedstrom DM, Pence MM, Chan VL,

Chambers MJ, Rogers SP, Seger NC, Riemann LA, Cohen HS. Early fortification of enteral feedings for infants <1250 grams birth weight receiving a human milk diet including human milk-based fortifier. J Neo-Perinatal Med. 13: 215-221, 2020.

1. Noël PH, Barnard JM, Barry FM, Simon A, Lee M, Olmos‐Ochoa TT, Chawla N, Rose

DE, Stockdale SE, Finley EP, Penney LS, Ganz DA. Patient experience of healthcare

system hassles: Dual system versus single system users. Health Services Research, 2020;

<https://doi.org/10.1111/1475-6773.1329>.

1. Guzman-Clark J, Yefimova M, Farmer MM, Wakefield BJ, Viernes B, Lee ML, Hahn TJ.

Home telehealth technologies for heart failure: An examination of adherence among veterans. J Geront Nurs 46: 26-34, 2020.

241. Lin AM, Vickrey BG, Barry F, Lee ML, Ayala-Rivera M, Cheng E, Montoya

AV, Mojarro-Huang E, Gomez P, Castro M, Corrales M, Sivers-Teixeira T, Tran JL, Johnson R, Ediss C, Shaby B, Willis P, Sanossian N, Mehta B, Dutta T, Razmara A, Bryg R, Song S, Towfighi A. Factors associated with participation in the Chronic Disease Self-Management Program. Findings from the SUCCEED Trial. Stroke, 2020; <https://doi.org/10.1161/STROKEAHA.119.028022>.

242. Nichols TM, Levy H, Merricks E, Raymer RA, Lee ML. Preclinical evaluation of a next-

generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.

PLOS One 15(10), 2020: e0240896. https://doi.org/10.1371/journal.pone.0240896.

243. Guzman-Clark J, Farmer MM, Wakefield BJ, Viernes B, Yefimova M, Lee M, Hahn TJ Why patients stop using their home telehealth technologies over time: Predictors of discontinuation in Veterans with heart failure. Nurs Outlook. 2020 Dec 2:S0029-6554(20)30696-5. doi: 10.1016/j.outlook.2020.11.004.

244. Guzman-Clark J, Wakefield B, Farmer M, Yefimova M, Viernes B, Lee M, Hahn T. Adherence to the use of home telehealth technologies and emergency room visits in Veterans with heart failure. Telemed J E Health. 2020 Dec 3. doi: 10.1089/tmj.2020.0312.

245. Tcheung LS, Cordasco KM, Danz M, Jackson L, Yuan A, Lee ML, Washington DL. Quality of care for women with urinary incontinence in the Veterans Health Administration. J Gen Intern Med. 2021 Sep;36(9):2900-2902. doi: 10.1007/s11606-020-06196-0. Epub 2020 Sep 15. PMID: 32935317.

246. You CW, Hong S-B, Kim S, Shin H-J. Kim JS, Han JW, Kim S-J, Kim DY, Lee M, Levy H. Safety, pharmacokinetics and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously-treated hemophilia B patients. J Thrombosis Haemostasis 2021 DOI: 10.1111/jth.15259.

247. Del Pino HE, Steers WN, Lee M, McCuller WJ, Hays RD, Harawa NT. Measuring

gender role conflict, internalized stigma and racial and sexual identity in behaviorally bisexual black men. Arch Sex Behavior, 2020; https://doi.org/10.1007/s10508-021-01925-w.

248. Hsia SH, Nisis ML, Lee ML, Goldstein C, Friedman TC. Metabolic parameters in smokers

undergoing smoking reduction. J Clin Transl Endocrin 2021. <https://doi.org/10.1016/j.jcte.2021.100249>

249. Towfighi A, Cheng EM, Ayala-Rivera M, Barry F, McCreath H, Ganz, DA, Lee ML, et al.

# Effect of a coordinated community and chronic care model team intervention vs. usual

# care on systolic blood pressure in patients with stroke or transient ischemic attack:

The SUCCEED Randomized Clinical Trial. JAMA Network Open. 2021;4(2):e2036227. doi:10.1001/jamanetworkopen.2020.36227.

250. Salvidar P, Mira V, Duran P, Moldovan C, Ang G, Parikh N, Lee ML, Friedman TC.

Implementing texting programs in the P.O.W.E.R. (preventing obesity with eating right)

medical group visit for weight loss. Obesity Science and Practice, 2021. doi:10.1002/osp4.513.

251. Mahlangu J, Levy H, Lee M, Del Greco F. Efficacy and safety of subcutaneous prophylaxis

with dalcinonacog alfa in adults with haemophilia B. Haemophilia, 2021;00:1-7.https://doi.org/10.1111/hae.14315.

252. Fleig L, Hagan J, Lee ML, Abrams SA, Hawthorne KM, Hair AB. Growth outcomes of

small for gestational age preterm infants before and after implementation of an exclusive human milk-based diet. J. Perinatology, 2021. <https://doi.org/10.1038/s41372-021-01082-x>.

253. Noel PH, Barnard JM, Leng M, Penney LS, Bharath PS, Olmos-Ochoa TT, Chawla N,

Rose DE, Stockdale SE, Simon A, Lee ML, Finley EP, Rubenstein LV, Ganz DA. The

Coordination Toolkit and Coaching Project: Cluster-randomized quality improvement

initiative to improve patient experience of care coordination. J. Gen Int Med, 2021.

doi: 10.1007/s11606-021-06926-y.

254. Mahlangu J, Levy H, Kosinova MV, Khachatryan H, Korczowski B, Makhaldiani H,

Iosava G, Lee M, Del Greco F. Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. Research Practice Thromb Haemo, 2021. doi.org/10.1002/rth2.12576.

255. Ogunyemi OI, Gandhi M, Lee M, Teklehaimanot S, Daskivich LP, Hindman D, Lopez K,

Taira R. Detecting diabetic retinopathy through machine learning on electronic health

record data from an urban, safety net healthcare system. JAMIA Open 19: 1-10, 2021.

256. Rosenson RS, Lee ML, Chen Q. Association of total VLDL particle concentrations with

elevated blood viscosity in patients with Type 2 diabetes. Diabetes Res Clin Prac, 2021.

doi.org/10.1016/j.diabres.2021.109180.

257. Kaufmann R, Aqua K, Lombardo J, Lee M. Observed impact of long-term consumption

of oral cannabidiol on liver function in healthy adults. Cannabis Cannabinoid Res. 2021.10.1089/can.2021.0114. doi:10.1089/can.2021.0114.

258. Scheuner MT, Huynh AK, Chanfreau-Coffinier C, Lerner B, Gable AR, Lee M, Simon A,

Coeshott R, Hamilton AB, Patterson OV, DuVall S, Russell MM. Demographic differences among US Department of Veterans Affairs patients referred for genetic consultation to a

centralized VA Telehealth Program, VA Medical Centers, or the community. JAMA Netw Open. 2022;5(4):e226687. doi:10.1001/jamanetworkopen.2022.6687.

259. Button JE, Autran CA, Reens AL, Cosetta CM, Smriga S, Ericson M, Pierce JV, Cook,

DN, Lee ML, Sun AK, Alousi AM, Koh AY, Rechtman DJ, Jenq RR, McKenzie GJ.

Dosing a symbiotic of human milk oligosaccharides and *B. infantis* leads to reversible

engraftment in healthy adult microbiomes without antibiotics. Cell Host & Microbe 2022.

doi.org/10.1016/j.chom.2022.04.001.

260. Tsai K, Inoue K, McClean M, Kaunitz JD, Akiba Y, Lee ML, Neverova NV, Currier JW,

Ebrahimi R, Bashier M, Leung AM. Iodine content exposure and incident COVID-19

infection. Frontiers Medicine 2022. 9:1033601. Doi:10.3389/fmed.2022.1033601.

1. Button JE, Autran C, Reens AL, Cosetta CM, Smriga S, Ericson M, Pierce JV,

Cook DN, Lee ML, Sun AK, Alousi AM, Koh AY, Rechtman DJ, Jenq RR, McKenzie GJ.

Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics. Cell Host Microbe

2022. 30(5):712-725.e7. doi: 10.1016/j.chom.2022.04.001. Epub 2022 May 2.

1. Reyes SM, Strott-Moore JR, Brooker SL, Lee ML, Ferry J, Huston RK, Elliott MJ.

Association of an exclusive human milk diet with morbidity and mortality in ELBW infants born ≤750 grams: An individual participant data meta-analysis. Neonatology Today 18: 3-23, 2023.

1. Frias JP, Lee ML, Carter MM, Ebel ER, Lai R-H, Riske L, Washington ME, Sonnenburg

JL, Damman CJ. A microbiome-targeted fibre-enriched nutritional formula is well tolerated

and improves quality of life and haemoglobin A1c in type 2 diabetes: A double-blind,

randomized, placebo-controlled trial. Diabetes Obes Metab. 2023 May; 25(5):1203-1212.

doi: 10.1111/dom.14967. Epub 2023 Jan 23. PMID: 36594522.

1. Than CT, Bean-Mayberry B, Schweizer CA, Lee M, Chantreau-Coffinier C, Clair K,

Hamilton AB, Farmer MM. Ask and ask again: Repeated screening for smoking increases likelihood of prescription for cessation treatment among women veterans. J Gen Intern Med. 2023 Aug;38(11):2553-2559. doi: 10.1007/s11606-023-08227-y. Epub 2023 Jun 5.

PMID: 37277666.

1. Button JE, Cosetta CM, Reens AL, Brooker SL, Rowan-Nash AD, Levin RC, Saur R,

Zheng S, Autran CA, Lee ML, Sun AK, Alousi AM, Peterson CB, Koh AY, Rechtman DJ,

Jenq RR, McKenzie GJ. Precision modulation of dysbiotic adult microbiomes with a

human-milk-derived symbiotic reshapes gut microbial composition and metabolites.

Cell Host & Microbe 2023. [doi.org/10.1016j.chom.2023.08.004](https://doi.org/10.1016j.chom.2023.08.004).

1. Meredith LR, Hurley B, Friedman TC, Lee ML, Rodriguez L, Lopez B, Mtume N,

Dixon T, Belani HK, Hsieh S, Ray LA. Implementation of specialty tobacco use disorder

services in a community health setting: Support for enhanced prescription services.

J Addict Med 2023; 17: 677-684.

1. Inoue K, Guo R, Lee ML, Ebrahimi R, Neverova NV, Currier JW, Bashir MT, Leung AM.

Iodine-Induced Hyperthyroidism and Long-term Risks of Incident Atrial Fibrillation and

Flutter. J Clin Endocrinol Metab. 2023 Sep 18;108(10):e956-e962. doi: 10.1210/clinem/dgad250. PMID: 37146179.

1. Inoue K, Guo R, Lee ML, Neverova NV, Ebrahimi R, Currier JW, Bashir MT, Leung AM.

Iodine-Induced Hypothyroidism and Long-Term Risks of Incident Heart Failure. J Am Heart Assoc. 2023 Oct 17;12(20):e030511. doi: 10.1161/JAHA.123.030511. Epub 2023 Oct 10. PMID: 37815042.

1. Jacobs JP, Lee ML, Rechtman DJ, Sun AK, Autran C, Niklas V. Human milk

oligosaccharides modulate the intestinal microbiome of healthy adults. Sci Rep. 2023 Aug

31;13(1):14308. doi: 10.1038/s41598-023-41040-5. PMID: 37652940; PMCID:

PMC10471580.

1. Reens AL, Cosetta CM, Saur R, Trofimuk O, Brooker SL, Lee ML, Sun AK, McKenzie

GJ, Button JE. Tunable control of B. infantis abundance and gut metabolites by co- administration of human milk oligosaccharides. Gut Microbes 2024, 16:1, DOI: 10.1080/19490976.2024.2304160.

1. Salley A, Lee ML. Proactive use of a human milk fat modular in the neonatal intensive care

unit: A Standardized Feeding Protocol. Nutrients 2024, 16, 1206, DOI: 10.3390/nu16081206.

1. Rivera JC, Espinoza-Derout J, Hasan KM, Molina-Mancio J, Martínez J, Lao CJ, Lee ML,

Lee DL, Wilson J, Sinha-Hikim AP, Friedman TC. Hepatic steatosis induced by nicotine

plus Coca-Cola™ is prevented by nicotinamide riboside (NR). Front Endocrinol

(Lausanne). 2024 May 2;15:1282231. doi: 10.3389/fendo.2024.1282231. eCollection 2024.

PMID: 38756999.

1. Wang J, Leung L, Jackson N, McClean M, Rose D, Lee ML, Stockdale SE. The association

between population health management tools and clinician burnout in the United States VA primary care patient-centered medical home. BMC Prim Care. 2024 May 15;25(1):164. doi: 10.1186/s12875-024-02410-8. PMID: 38750457.

1. Sohn SY, Inoue K, Bashir MT, Currier JW, Neverova NV, Ebrahimi R, Rhee CM, Lee ML,

Leung AM. Thyroid dysfunction risk after iodinated contrast media administration: A

prospective longitudinal cohort analysis. J Clin Endocrinol Metab. 2024 May 3:dgae304.

doi: 10.1210/clinem/dgae304. Online ahead of print. PMID: 38700099.

1. Leung L, Chu K, Lee M, Bonilla AG, Post EP, Fortney J. Depression and

suicide risk screening in the Veterans Health Administration: An interrupted time

series analysis. JAMA Network Open. 2024;7(12):e2451936. doi:10.1001/jamanetworkopen.2024.51936.

1. Wilson JB, Hoang TD, Lee ML, Epstein M, Friedman TC. Reverse T3 in patients

with hypothyroidism on different thyroid hormone replacement. PLOS ONE 2025 20(6):

e0325046. <https://doi.org/10.1371/journal.pone.0325046>

1. Haderlein T, Lov D, Bonilla A, Lee M, Leung LB. Association between telehealth delivery

and same-day access to integrated mental health in a national VA sample. Journal of

General Internal Medicine 2025. In press.

# CONTRIBUTED PAPERS (abstracts)

1. Lee ML. Answer booklet to Applied Statistics, UCLA Division of Biostatistics, 1978.

2. Lee ML, and Cumberland, W.G. An unbiased estimate for the reciprocal of the mean of a normal distribution, Technical Report, UCLA Division of Biostatistics, 1980.

3. Lee ML, and Chang PC. Some nearest neighbor estimators for the inverse regression problem, ASA Meeting, Detroit, Michigan, 1981.

4. Lee ML, Kantrowitz JL, and Taylor MG. Statistical methods for validating Q.C. tests, 36th ASQC Annual Technical Congress Transactions, 717-723, 1982.

5. Lee ML, Kantrowitz J, and Taylor M. Statistical methods for validating Q.C. tests, ASQC Annual Technical Conference, Detroit, Michigan, 1982.

6. Taylor MG, Kantrowitz JL, and Lee ML. Developing a validation program for Q.C. tests, 37th ASQC Annual Technical Congress Transactions, 493-95, 1983.

7. Lee ML, and Kingdon HS. Methods for the analysis of Factor VIII half-life data, IXth Congress on Thrombosis and Hemostasis, Stockholm, 1983.

8. Lee ML and Kingdon HS. Methods for the analysis of Factor VIII half-life data, Thrombosis and Hemostasis, 50 (1), 245, 1983.

9. Lee ML, Kantrowitz JL, and Mullis CE. Sample size, cross-over trials and the problem of treatment equivalence, American Statistical Association, Proceedings of the Biopharmaceutical Section, 78-80, 1984.

10. Lee ML, and Chang PC. A nearest neighbor estimation scheme for radioimmuno-

assays, XIIth International Biometrics Conference, Tokyo, 1984.

11. Lee ML, and Mullis C. Sample size, cross-over trials, and the problem of treatment equivalence, ASA Meeting, Philadelphia, 1984.

12. Fischer S, Lee ML, Ochs H, Kingdon HS, and Wedgwood R. A study of the safety and efficacy of a new intravenous immunoglobulin preparation (Gammagard®), American Society of Hospital Pharmacists, Dallas, 1984.

13. Fischer S, Lee ML, Ochs H, Kingdon HS, and Wedgwood RA. Study of the prevention of infections in primary immunodeficients with a new intravenous immunoglobulin preparation (Gammagard®), American Association for Clinical Immunology and Allergy, New Orleans, 1984.

14. Lee ML. "Proving" the null hypothesis with paired qualitative data, American Statistical Association, Proceedings of the Biopharmaceutical Section, 106-108, 1985.

15. Hooper J, Andrews J, Holst SL, Kingdon HS, Lee ML, Mankarious S, McDougal S, Slimak W, and Piszkiewicz D. The safety of immunoglobulin preparations containing antibody to LAV/HTLV-III, Second Meeting of the European Group for Immunodeficiencies, Kerkade, The Netherlands, 1986.

16. Hooper J, Kingdon H, Lee M, Mankarious S, Schneider H. Retrospective and prospective studies of serum transaminase levels in patients receiving intravenous immune globulin, Second Meeting of the European Group for Immunodeficiencies, Kerkade, The Netherlands, 1986.

17. Piszkiewicz D, Kingdon HS, Lee ML, and Hooper J. The incidence of HTLV-III/LAV seroconversion and non-a, non-B hepatitis in recipients of plasma products, International Association of Biological Standardization Symposium, Melbourne, 1986.

18. Lee ML, and Lusher J. Clinical trials using hemophiliacs with inhibitors to Factor VIII, American Public Health Association Annual Meeting, Las Vegas, 1986.

19. Addiego JE, Bailey P, Bradley M, Courter SG, and Lee ML. Recovery and survival studies of a new Factor VIII product, XIth International Congress on Thrombosis and Hemostasis, Brussels, 1987.

20. Lee ML, Courter S, Tait D, and Kingdon H. A long-term evaluation of an intravenous immune globulin preparation (Gammagard®) with regards to non-A, non-B hepatitis safety, International Symposium on Viral Hepatitis and Liver Disease, London, 1987.

21. Kingdon H, Lee M, Addiego JE, Gomperts E, Kessler C, and Griffith M. Ultrapure plasma Factor VIII produced by anti-FVIIIC immunoaffinity chromatography and solvent/detergent viral inactivation, 39th Annual Meeting of the National Hemophilia Foundation, Omaha, 1987.

22. Chapel HM, Griffith H, Brennan V, Lea J, Bunch C, and Lee ML. A cross-over study of the use of intravenous immunoglobulin for prophylaxis against infection in patients with chronic lymphocytic leukemia or low grade non-Hodgkin's lymphoma. American Federation of Clinical Research 1988 (abstract).

23. Gomperts E, Addiego J, Gill J, Levine P, Kessler C, Schulman S, Lewis B, Brackmann H, Courter S, and Lee M. Impact of monoclonally purified plasma derived FVIII concentrate on immunological function in hemophiliacs. American Society of Hematology, San Antonio, 1988.

24. Courter S, Lee M, Addiego JE, Gomperts E, Kessler C, Griffith M, and Kingdon H. Ultrapure plasma Factor VIII produced by anti-FVIII immunoaffinity chromatography and solvent/detergent viral inactivation. American Federation for Clinical Research, 1988.

25. Liu S, Addiego J, Gomperts E, Kessler C, Garanchon L, Neslund G, Foster V, Berkebile R, Courter S, Lee M, Kingdon H, and Griffith M. A plasma factor VIII:C concentrate purified by immunoaffinity. 2nd Bari International Congress on Factor VIII and von Willebrands' Factor: Biological and Clinical Advances, 1988.

26. Chapel HM, Griffiths H, Brennan V, Lea J, Bunch C, Lee M, and Kingdon HS. Prevention of bacterial infections by administration of intravenous immunoglobulin: A cross-over study. Central Society for Clinical Research, Chicago, 1988.

27. Gomperts ED, Willoughby A, Hilgartner M, Hoots K, Lee M, Warrier I, Aledort L, Andes A, Eyster E, Kisker T, Parmley R, and Sexauer C. Survey of hemophiliac children HIV status, growth and development. XVIIIth International Congress of the World Federation of Hemophilia, Madrid, 1988.

1. Gomperts E, White G, Mannucci PM, Roberts H, Courter S, and Lee M. Recombinant Factor VIII clinical trial: Lack of inhibitory response and surgical efficacy. XIIth International Society for Thrombosis and Hemostasis Meeting, Tokyo, 1989.

29. Gomperts E, Addiego J, Gill J, Levine P, Kessler C, Schulman S, Lewis B, Brackmann H, Courter S, and Lee M. Immunological function in hemophiliacs treated with plasma derived MAb purified Factor VIII concentrate. XIIth International Society for Thrombosis and Hemostasis Meeting, Tokyo, 1989.

30. Baker CJ, and the Neonatal IGIV Collaborative Study Group (includes S Courter, B Bagby, M Lee). Multicenter trial of intravenous immunoglobulin (IGIV) to prevent late-onset infection in preterm infants: Preliminary results. Society for Pediatric Research, Washington, D.C., 1989.

31. Gomperts E, Addiego J, Gill J, Levine P, Kessler C, Schulman S, Lewis B, Brackmann H, Scharrer I, Courter S, and Lee ML. Immunological function in hemophiliacs treated with plasma derived MAb purified FVIII concentrate. XIIth International Society for Thrombosis and Hemostasis Meeting, Tokyo, 1989 and National Hemophilia Foundation Meeting, Chicago, 1989.

32. Kingdon HS, Liu SL, Bagby B, Cox D, Gracien E, Lee ML, Courter S. Preliminary results of Recombinate™ clinical safety and efficacy. National Hemophilia Foundation Meeting, Chicago, 1989.

33. Lee M, White G, Morfini M, Courter S, Kingdon H. Comparison of recombinant and monoclonally-purified AHF pharmacokinetics: the use of a two-phase linear regression model. American Society of Hematology Meeting, Atlanta, 1989.

34. Gomperts E, Addiego J, Gill J, Levine P, Kessler C, Schulman S, Lewis B, Lee M, and Courter S. The effect of purified, plasma derived FVIII on immune function in hemophilia A patients. American Society for Hematology Meeting, Atlanta, 1989.

35. White G, MacMillan C, Gomperts E, Addiego J, Brackmann H, Brettler D, Gill J, Goldsmith J, Hoots K, Kessler C, Kisker T, Laurian Y, Lewis B, Lusher J, Mannucci P, Morfini M, Scharrer I, Schulman S, Lee M, Courter S, Kingdon H, Roberts H. Safety and efficacy of human factor VIII prepared by recombinant DNA techniques. American Society of Hematology Meeting, Atlanta, 1989.

36. Gomperts E, Mannucci PM, White G, MacMillan C, Addiego J, Brackmann H, Brettler D, Gill J, Goldsmith J, Hoots K, Kessler C, Kisker T, Laurian Y, Lewis B, Lusher J, Morfini M, Scharrer J, Schulman S, Lee M, Courter S, Kingdon H, Roberts H. Recombinate™ (Antihemophilic Factor [Recombinant]) Clinical Trial: Safety, Pharmacokinetics and Surgical Efficacy, Proceedings of the 6th International Symposium of Hemostasis and Thrombosis, 39-49, 1990.

1. Cometta A, Baumgartner JD, Lee M, Glauser MP, and the Anti-Core LPS IVIG Collaborative Study Group. Prophylaxis of infection in high risk surgical patients (pat) with standard intravenous immunoglobulin G (St-IVIG) or with antibody to core glycolipid (co-IVIG). 30th ICAAC, Atlanta, 1990.

38. White GC, MacMillan CW, Gomperts ED, Addiego JE, Brackmann HH, Brettler DE, Gill JC, Goldsmith JC, Hoots WK, Kessler CM, Kisker CT, Laurian Y, Lewis B, Lusher JM, Mannucci PM, Morfini M, Scharrer I, Schulman S, Lee ML, Courter SG, Kingdon HS, and Roberts HR. Clinical trials of recombinant factor VIII produced by recombinant technology. American Red Cross Conference, Washington, D.C., 1990.

39. Hargreaves R, Griffiths H, Faux J, Holt J, Bunch C, Lea J, Reid C, Lee M, Chapel H. Infection and immunological responses in myeloma. International Society of Hematology 23rd Congress, Boston, 1990.

40. Chapel H, Hargreaves R, Lee M, Pamphilon D, et al. Use of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. European Group for Immune Deficiencies, Lugano, Switzerland, 1992.

41. Strand V, Lee M, Lipsky PE, Cannon G, Olsen N, and the CD5 Plus RA Investigators Group. Patterns of response to clinical outcome measures observed in two phase II studies of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. American College of Rheumatology Annual Meeting, Atlanta, 1992.

42. Lee ML, Liu-Maruya S, Courter S, and Gomperts E. Determining inhibitor-development risk in previously untreated hemophilia A patients (PUPs) treated with recombinant Factor VIII (Recombinate™). American Society for Hematology (abstract), New Orleans, 1992.

43. Lee ML, Courter S, and Gomperts E. Determining inhibitor-development risk in previously untreated hemophilia A patients (PUPs) treated with recombinant Factor VIII (Recombinate™). XIVth Congress of the International Society on Thrombosis and Haemostasis, New York, 1993.

1. Bray GL, Courter S, Lynes M, Lee M, Gomperts E, and the Recombinate Study Group. Safety, efficacy and inhibitor risk of recombinant Factor VIII (Recombinate®) in a cohort of previously untreated patients (PUPs) with severe hemophilia A. XIVth Congress of the International Society on Thrombosis and Haemostasis, New York, 1993.
2. Lee ML, Courter SG, and the Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Quality of life assessment versus clinical outcome measures in chronic lymphocytic leukemia patients receiving intravenous immunoglobulin. Drug Information Association 1st Annual Symposium of Contributed Papers on Quality of Life, Charleston, South Carolina, 1993.

46. Rechtman DJ, Ulrich JT, Von Eschen K, Vargas R, and Lee M. Circulating cytokine levels following infusion of MPL® are modified by steroid in a dose dependent sometimes biphasic manner. ICAAC, New Orleans, 1993.

47. Lee ML, Courter SG, and Gomperts E. Further determinants of the inhibitor-development risk in previously untreated patients receiving recombinant Factor VIII (Recombinate®). 2nd International Symposium on Inhibitors to Coagulation Factors, Chapel Hill, North Carolina, 1993.

48. Hoots WK, McLeod J, Eggers E, Berg J, Lee M, and Gomperts E. Pilot study to evaluate efficacy of fibrin sealant (human) on hemostasis in hemophiliacs undergoing tooth extraction. American Society for Hematology, St. Louis, 1993.

49. Spertini F, Leimgruber A, Petrocelli A, Khazaeli MB, Yamamoto K, and Lee M. Preliminary clinical results with an idiotypic vaccine (3E10) for systemic lupus erythematosus (SLE). Scandinavian Congress of Rheumatology, Lillehammer, Norway, 1994.

1. Lee ML, Spertini F, Leimgruber A, Petrocelli A, Fine H, Strand V, and Yamamoto K. Phase 1 clinical results with an idiotypic vaccine (3E10) for systemic lupus erythematosus (SLE), American College of Rheumatology 58th Annual Meeting, Minneapolis, 1994.

51. Bray GL, Schroth P, Lynes M, Buckwalter C, Lee ML, and Gomperts ED for the Recombinate Study Group. Results from the Recombinate™ (recombinant Factor VIII) study of previously untreated patients with hemophilia A: a 4.5 year follow-up report. XVth Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, Israel, 1995.

52. Lee M, Kessler C, White GC, Gomperts ED, and Courter SG. The pharmacokinetics of recombinant factor VIII (Recombinate™) under continuous infusion. XVth Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, Israel, 1995.

53. Chernof BA, Sherman SE, Lanto AB, Lee ML, Rubenstein L. Which patients receive health habits counseling? 18th Annual Meeting of the Society of General Internal Medicine, Washington, D.C., 1995.

54. Lee ML, Wang MM, Lanto A, Yano EM, Rubenstein LV. An appraisal of visit-based sampling for the evaluation of ambulatory care. 13th Annual HSR&D Service Meeting, Washington, D.C., 1995.

55. Chang DS, Chernof BA, Lanto AB, Yano EM, Lee M, and Rubenstein LV. The effect of active coronary artery disease on health and functional status: an ambulatory needs

assessment. 18th Annual Meeting of the Society of General Internal Medicine, Washington, D.C., 1995.

56. Lee ML, Lanto AB, Rubenstein LV. The problem of data analysis arising from a longitudinal study based on a cluster sampling scheme. 1st International Conference on Health Policy Research: Methodologic Issues in Health Services and Outcomes Research, Cambridge, Mass, 1995.

57. Van Tilborg L, Gomperts E, Bray G, Lee M. Use of solvent-detergent treated immune globulin intravenous (Human) [IGIV] in patients at high risk for adverse reactions. 35th ICAAC, San Francisco, 1995.

58. Lee ML, Spertini F, Leimgruber A, Klashman D, Petrocelli A, Khazaeli MB, Strand V, Gibson DA, and Yamamoto K. Phase I clinical results with an idiotypic vaccine (3E10) for systemic lupus erythematosus (SLE). 4th International Conference on Systemic Lupus Erythematosus, Jerusalem, 1995.

59. Lee ML, Spertini F, Leimgruber A, Klashman D, Petrocelli A, Khazaeli MB, Strand V, Gibson DA, and Yamamoto K. Updated phase I clinical results with an idiotypic vaccine (3E10) for systemic lupus erythematosus (SLE). American College of Rheumatology 59th Annual Meeting, San Francisco, 1995.

60. Spertini F, Leimgruber A, Morel B, Klashman D, Petrocelli A, Khazaeli MB, Yamamoto K, Lee ML. Vaccination idiotypique dans la nephiste lupique: Resultats intermediaires d’une etude de phase I. Assemblee annuelle de la Societe Swisse de Medecine Interne, Montreux, 1995.

1. Lee CA, Pasi KJ, Owens D, Barrowcliffe T, Kimball-Cook G, Bray G, Van Tilborg L, Lee M, Gomperts ED. Comparison of half life of method M purified AHG (Hemofil M) by one-stage and chromogenic substrate assay methods. American Society of Hematology Annual Meeting, Seattle, 1995.
2. Lee ML, Bray G, Mosher J, Gau J, and Gomperts ED. An improved, robust method for the determination of coagulation factor half-life. World Federation of Hemophilia Meeting, Dublin, Ireland, 1996.
3. Chernof BA, Sherman SE, Lanto AB, Lee ML, Rubenstein LV. Which patients receive health habits counseling? Society of General Internal Medicine National Meeting, San Diego, 1996.
4. Damron-Rodriguez JA, DeJong F, Tseng HF, Lee M. Neighborhood crime and allocation of home health services in Los Angeles. Gerontological Society of America Annual Meeting, Washington, DC, 1996.

65. Zwischenberger JB, Atkinson JB, Gomperts ED, Bray G, Dedrick L, Kang R, Lee M, Arensman R, Bartlett RH, Raes-Bharami K, Breaux CW, Cornish JD, Hasse GM, Roden J. Clinical efficacy of fibrin sealant as a topical hemostatic agent in

extracorporeal membrane exygenation (ECMO) patients. International Conference on Fibrinogen, Canberra, 1996.

66. Atkinson JB, Gomperts ED, Kang R, Lee M, Arensman RM, Bartlett RH, Rais-Bharami K, Breaux CW, Cornish JD, Haase GM, Roden J, Zwischenberger JB. Prospective, randomized evaluation of the efficacy of fibrin sealant in neonates undergoing ECMO. American Society of Hematology Annual Meeting, Orlando, 1997.

67. Lee ML, Tomsu K, Von Eschen K. A meta-analysis of median survival of patients with stage IV melanoma. American Society of Clinical Oncology, Annual Meeting, Denver, 1997.

68. Grimm CT, Kosower E, Wang M, Lee M. Videotape review and feedback: not enough bang for the buck? VA HSR&D Annual Meeting, Washington, DC, 1997.

69. Kerr EA, Hays RD, Lee ML, Siv AL. Does dissatisfaction with access to specialists affect the desire to leave a health plan? VA HSR&D Annual Meeting, Washington, DC, 1997.

70. Shekelle PG, Kravitz RL, Beart J, Marger MD, Wang MM, Lee M. Are nonspecific practice guidelines potentially harmful? A randomized comparison of the effect of nonspecific or specific guidelines on physician decision making. VA HSR&D Annual Meeting, Washington, DC, 1997.

71. Lee ML, Fink A, Wang MM. Accounting for patient clustering effect in health policy research studies: A review of the literature. Association for Health Services Research Annual Meeting, Chicago, 1997.

72. Lee ML, Schroth P, Bray G, Gomperts ED. The use of robust regression techniques to obtain improved coagulation factor half-life estimates. XVIth Congress of the International Society for Thrombosis and Hemostasis, Florence, Italy, 1997.

73. Lee ML, Schroth P, Bray G, Gomperts ED. Determination of inhibitor-risk after receiving significant amounts of factor VIII concentrates. XVIth Congress of the International Society for Thrombosis and Hemostasis, Florence, Italy, 1997.

1. Lee ML. The design and analysis of clinical studies for fibrin sealant. XVIth Congress of the International Society for Thrombosis and Hemostasis, Florence, Italy, 1997.
2. Bray GL, Gomperts ED, Lee M, Navalta L and the Fibrin Sealant Viral Safety Study Group. Viral safety results of solvent-detergent treated fibrin sealant (human) administered to burn patients undergoing skin graft procedures. XVIth Congress of the International Society for Thrombosis and Hemostasis, Florence, Italy, 1997.

76. Ortel TL, Neal MC, Thames EH, Moore K, Klemp K, Kane WH, Lee ML, Navalta L, Lawson JH. Prospective evaluation following surgical exposure to bovine thrombin. XVIth Congress of the International Society for Thrombosis and Hemostasis, Florence, Italy, 1997.

77. Lee M, Bray G, Reilly J. Modelling the differential rate of blood donors with Crutzfeld-Jacob Disease (CJD) in paid versus unpaid donor populations. World Federation of Hemophilia Annual Meeting, The Hague, 1998.

78. Lee ML, Wang MM, Yano EM, Rubenstein LV. An association between the frequency of primary care clinic visits and hospitalization survival. VA HSR&D Annual Meeting, Washington, DC, 1998.

79. Saliba D, Kington R, Buchanan J, Bell R, Wong M, Lee M, Herbst M, Lee D, Sur D, Rubenstein LV. The quality of the provider decision to transfer nursing facility patients to the hospital. VA HSR&D Annual Meeting, Washington, DC, 1998.

80. Wilkes M, Lee M, Wang MM, Rubenstein L, Kalich J. The nature of continuing medical education courses taken by physicians in California. VA HSR&D Annual Meeting, Washington, DC, 1998.

81. Yano EM, Lee M, Wang MM, Rubenstein LV. Determinants of primary care firm system development. VA HSR&D Annual Meeting, Washington, DC, 1998.

82. Kerr EA, Hays RD, Mitchinson AR, Lee M, Siu AL. The influence of gatekeeping and utilization review to restrict access to specialists on patient satisfaction with care. VA HSR&D Annual Meeting, Washington, DC, 1998.

83. Ofman J, Etchason J, Hirsh T, Simon B, Lee M, Fox S, Kanouse D. Should clinical context influence prescribing practices. VA HSR&D Annual Meeting, Washington, DC, 1998.

84. Landis CA, Nugent ME, Asch S, Yano EM, Lee M, Wang M, Krut J, Rubenstein L. Comparison of self-care center hemodialysis to conventional center hemodialysis: A single center observational study. VA HSR&D Annual Meeting, Washington, DC, 1998.

85. Peabody J, Dresselhaus T, Glassman P, Lee M, Luck J. Are clinical vignettes better than chart abstraction to measure quality? VA HSR&D Annual Meeting, Washington, DC, 1998.

86. Lee M, Yano EM, Mittman B, Rubenstein L. Evaluating health care organizational change: Benefits and limitations of hierarchical and structural equation modeling. VA HSR&D Annual Meeting, Washington, DC, 1998.

87. Lee M, Fink A, Wang MM. Accounting for patient clustering effect in health policy research studies: A review of the literature. VA HSR&D Annual Meeting, Washington, DC, 1998.

1. Yano EM, Lee M, Wang M, Rubenstein LV. Effects of primary care program features on adjusted hospitalization rates. VA HSR&D Annual Meeting, Washington, DC, 1998.
2. Lee M, Landis CA, Wang M, Yano E. Establishing clinical equivalence: An example from a study of self-care center versus full-care hemodialysis. VA HSR&D Annual Meeting. Washington, DC, 1999.
3. Lee M, Wang M, Yano E, Rubenstein L. Evaluating the effect of primary care clinic visits on survival for hospitalization. VA HSR&D Annual Meeting. Washington, DC, 1999.
4. Lee M, Smith BL, Leader S, Westlake P. The economic impact of automated primary screening for cervical cancer: Use of a Markov chain model. VA HSR&D Annual Meeting. Washington, DC, 1999.
5. Lee M. Evaluating health care organizational change: Benefits and limitations of hierarchical and structural equation modeling. VA HSR&D Annual Meeting. Washington, DC, 1999.
6. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. VA HSR&D Annual Meeting. Washington, DC, 2000.
7. Lee ML, Rubenstein LV, Yano EM. Techniques of data weighting and missing value imputation. VA HSR&D Annual Meeting. Washington, DC, 2001.
8. Lee ML, Sherman SE, Yano EM. Lack of clustering in a group randomized trial of smoking cessation guideline implementation (QUITS). HSR&D Annual Meeting. Washington, DC, 2001.
9. Lee ML, Rubenstein LV, Yano EM. Design strategies and statistical approaches to evaluating healthcare provider behavior change. HSR&D Annual Meeting. Washington, DC, 2002.
10. Cradock JA, Young AS, Yano EM, Wang M, Lee M. Evaluating the impact of mental illness on access to medical care. HSR&D Annual Meeting. Washington, DC, 2002.
11. Cradock JA, Young AS, Yano EM, Wang MM, Lee ML. Evaluating the impact of mental illness on medical care access. 82nd Annual Convention of Western Psychological Association, Irvine, CA, 2002.
12. Friedman TC, Davoudi S, Daigle K, Barron DS, Lee ML, Poland RE. Renin-aldosterone axis and orthostatic hypertension in patients with CFS. 6th International Conference on Chronic Fatigue Syndrome, Fibromyalgia and Related Illnesses, 2003.
13. Lee ML, Zangwill K, Ward J. Evaluating vaccine safety data using Markov chains. American Statistical Association Annual Meeting. San Francisco, CA, 2003.
14. Kim HS, Zuckerbraun E, Daigle K, Lee ML, Friedman TC. High prevalence of rennin-aldosterone axis abnormalities in patients with Chronic Fatigue Syndrome (CFS). Western Society for Clinical Research Meeting. Carmel, CA, 2004.
15. Chodosh J, Berry E, Lee M, Connor K, DeMonte R, Ganiats T, Rubenstein L, Vickrey B, A dementia quality of care intervention: Impact on physician knowledge, attitudes, and perceptions of care quality. American Geriatrics Society, 2004.
16. Vickrey BG, Connor KI, Mittman B, Chodosh J, Ganiats T, Della Penna R, DeMonte R, Pearson M, Cui X-p, Lee M. A cluster randomized controlled trial of a quality of care intervention for dementia. American Neurological Society, 2004.
17. Lee ML and Roth DR. A Bayesian approach to the assessment of inhibitor risk in studies of Factor VIII concentrates. International Society for Thrombosis and Haemostasis Meeting, Sydney, Australia, 2005.
18. Lee ML. The use of hierarchical linear models to evaluate methods for the delivery of primary care. American Statistical Association Annual Meeting, Seattle, WA, 2006.
19. Lee ML. Evaluation of results from collaborative study SSC8. International Society for Thrombosis and Haemostasis Meeting, Oslo, Norway, 2006.
20. Lee ML. The design and analysis of pharmacokinetic studies of coagulation factors. World Federation of Hemophilia Meeting, Vancouver, Canada, 2006.
21. Lee ML. Statistical methods for fraud investigations. National Health Care Anti-Fraud Association Meeting, Marco Island, Florida, 2006.
22. Lee ML. Evaluation of results from collaborative study SSC9. International Society for Thrombosis and Haemostasis Meeting, Geneva, Switzerland, 2007.
23. Gomperts ED, Lee M, Nichols T, Griffith M. IB1001, a new recombinant factor IX preparation: initial safety and characterization. International Society for thrombosis and Haemostasis Meeting, Boston, MA, 2009.
24. Lee ML. Design of studies for evaluating factor VIII and IX products. International Society for Thrombosis and Haemostasis Meeting, Cairo, Egypt, 2010.
25. Lee ML, Apte SJ, Morfini M, Ramanan V, Escobar M, Kempton C, Lubetsky A, Valentino L, Makris M, Negrier C, Mannucci PM, Mills B, Gomperts E. Use of IB1001, a new investigational factor IX, in patients with hemophilia B undergoing major surgical procedures. Fifth Annual Congress of the European Association for Haemophilia and Allied Disorders, Rome, Italy, 2012.
26. Scheuner MT, Hamilton AB, Peredo J, Sale TJ, Austin C, Gilman SC, Bowen MS, Goldzweig CL, Lee ML, Mittman BS, Yano EM. An innovative approach to documentation and use of the cancer family history by primary care clinicians that improves access to genetic services ACMG, Phoenix, 2013.
27. Sinha-Hikim, I., Duran, P., Shen , R., Lee, M.L., Friedman, T.C., Davidson, M.B. Effects of long term supplementation of vitamin D on inflammation, cytokines, thrombosis and IGF-1 levels in minority subjects with pre-diabetes and hypovitaminosis D. Endocrine Soc. 95: SUN-268, 2013.
28. Lee JXW, Wojtczak H, Wachter AM, Lee M, Burns L, Chen D, Yusin J. Understanding asthma medical nonadherence in adult and pediatric populations. AAAAI Annual Meeting, San Diego, CA, 2014 (abstract 11432-oral presentation).
29. Refaai MA, Goldstein JN, Lee ML, Milling TJ, Sarode R. Increased risk of volume overload with plasma compared to 4-factor prothrombin complex concentrate (4F-PCC) for the emergency reversal of vitamin K antagonist (VKA) therapy. Society for Academic Emergency Medicine, Abstract 585, 2014.
30. Scheuner MT, Marshall N, Lanto A, Lerner B, Oishi S, Hamilton AB, Lee M, Yano EM. Delivery of genetic consultative services in the Veterans Health Administration. AcademyHealth Meeting, San Diego,CA, 2014.
31. Hardesty BM, Plum S, Thibaudeau K, Lee M, Shapiro AD. Pharmacokinetics of Glu-plasminogen in patients with hypoplasminogenemia. American Society for Hematology Annual Meeting, Orlando, FL, Abstract 83747, 2015.
32. Lam CA, Sherbourne C, Gelberg L, Lee M, Huynh A, Chu K, Strauss J, Metzher M, Post E, Rubenstein L. Differences in Depression Care for Men and Women Among Veterans with and without Psychiatric Co-Morbidities. Poster session presented at: AcademyHealth Annual Research Meeting; 2016 Jun 26; Boston, MA.
33. Lam CA, Sherbourne CD, Gelberg L, Lee ML, Huynh AK, Chu K, Strauss JL, Post EP, Rubenstein LV, Farmer Coste MM. Differences in depression care for men and women among Veterans with and without psychiatric comorbidities. Poster session presented at: AcademyHealth Annual Research Meeting; 2016 Jun 26; Boston, MA.
34. Washington DL, Danz M, Tcheung LS, Jackson L, Yuan A, Lee M, Cordasco KM.  quality of care for women with urinary incontinence in the Veterans Health Administration - Comparison with community settings. Accepted for poster presentation at Academy Health 2017 Annual Research Meeting, New Orleans, LA, June 2017.
35. Huynh AK, Rose DE, Lee ML, Rubenstein LV, Stockdale SE. Evaluation of patient-assessed provider communication in Veterans Assessment and Improvement Laboratory (VAIL) QII using non-randomized stepped wedge design. Oral presentation at the 2017 HSR&D/QUERI National Conference, Crystal City, VA, July 2017.

1. Levy H, Kosinova MV, Khacchatryan H, Makhaldianai L, Iosavas G, Mahlangu J, Lee ML, Del Greco F, Booth FVM. Phase 2/3 study of subcutaneous engineered FVIIa marzeptacog alfa (activated) in hemophilia A or B with inhibitors: pharmacokinetics, pharmacodynamics, efficacy and safety. EAHAD Meeting, Prague, February, 2019.
2. Scheuner, MT, Huynh AK, Chanfreau-Coffinier C, Lerner B, Gable AR, Lee M, Simon A, Coeshott R, Panizzon K, Lewis L, Eyre H, Patterson OV, Russell MM. Unintended consequences of a population-based genetics program: An intervention to increase access may increase disparities. ACMG Clinical Meeting, San Antonio, March, 2020.

**OTHER PUBLICATIONS**

1. Book Review: Comprehensive Analytical Chemistry Vol. 11, G. Svehla, Ed., Clinical Chemistry, October, 1981.

2. Book Review: Chow SC, Liu, J.P. Design and Analysis of Bioequivalence Studies, J. Amer. Stat. Assoc., 88: 1169, 1993.

**INVITED PAPERS**

1. Lee ML. Statistical techniques for inverse estimation with application to radioimmunoassays, Biometrics Society (WNAR) Meeting, Eugene, Oregon, 1978.
2. Lee ML. Application of the negative binomial distribution to a problem in clean area testing, Parenteral Drug Association Summer Meeting, New York City, 1982.
3. Lee ML, Kingdon, H.S., Holst, S.L., and Hooper, J. Clinical evidence for the lack of seroconversion of LAV/HTLV-III in patients receiving blood products manufactured by Hyland Therapeutics, WHO Conference on the Safety of Blood Products, Geneva, 1986.
4. Lee ML. Clinical directions in intravenous immunoglobulin use, Oklahoma Society of Hospital Pharmacists Winter Meeting, Oklahoma City, 1987.
5. Lee ML. Hyland monoclonal factor VIII trial-preliminary result, U.C. Irvine Medical Center Hemophilia Symposium, Irvine, 1988.
6. Lee ML. A two-phase linear regression model for biological half-life data, Department of Statistics Seminar, Chinese University of Hong Kong, Shatin, Hong Kong, 1989.
7. Lee ML. Statistical validity of quality control tests, 1st International Conference on Pharmaceutical Quality Control, New Brunswick, New Jersey, 1990.
8. Lee ML. Pharmacokinetics of IgG subclasses, 3rd Symposium of Immune Deficiencies, Warsaw, Poland, 1990.
9. Lee ML. Assays of recombinant factor VIII products, Factor VIII Standardization Meeting, National Institute for Biological Standards and Control, London, 1990.
10. Lee ML. Pharmacokinetic methods for factor VIII. International Society for Thrombosis and Hemostasis Meeting, Barcelona, 1990.
11. Lee ML. Cost effectiveness, quality of life measures, and clinical trials. Regulatory Affairs Professional Society Annual Meeting, Washington, D.C., 1992.
12. Lee ML. Outcomes and new standards for product innovation - functional changes to meet demands. Conference on Capitalizing on Health Care Reform, Chicago, 1993.
13. Lee ML and Courter S.G. Quality of life and cost-effectiveness issues in chronic lymphocytic leukemia: A re-evaluation. Symposium on Drugs, Drug Companies, and Quality of Life Issues, New York, 1993.
14. Lee ML. Clinical trials on biologic products. Regulatory Affairs Professional Society, 18th Annual Conference, Washington, D.C., 1994.
15. Lee ML. A two phase linear regression model for the analysis of pharmacokinetic data. Conference on Pharmacokinetic Analysis: Accelerating Drug Development in Clinical Trials, Washington, D.C., 1994.
16. Lee ML. New approaches to the evaluation of the cost effectiveness of the treatments for chronic diseases. Drugs, Quality of Life, and Clinical Trials: Future Directions in the United States and Japan, New York, 1995.
17. Lee ML. Further investigations of the cost effectiveness of intravenous immunoglobulin in B-cell disease. Second National Symposium: Drugs, Drug Companies, and Quality of Life Issues in the Managed Care Setting, New York, 1996.
18. Lee ML. The combination of quality of life and survival data to evaluate therapies for stage 4 malignant melanoma. Symposium on Pharmaceuticals in the Palliative Care of Diseases of Differing Etiologies: Pharmaceutical Financial Opportunities, New York, 1998.
19. Lee ML. Accounting for patient clustering in health services research and policy literature. RAND workshop: Using Hierarchical Models and Structural Equations to Study Health Care Quality: Accounting for the Organizational Context, RAND Corporation, Santa Monica, CA, 1998.
20. Lee ML. The design and analysis of pharmacokinetic studies of coagulation factors. Grand Rounds, Aflac Cancer Center and Blood Disorders Service, Childrens’ Healthcare of Atlanta, 2006.
21. Lee ML. Current research with human milk. Focus on Human Milk Conference,

Maastricht, The Netherlands, 2008.

**DISSERTATION TITLE**

Some nearest neighbor estimators for the inverse regression problem with application to instrument calibration and radioimmunoassay

.

**OTHER RELEVANT ACADEMIC PROGRAMS**

Accounting Concepts for Non-Financial Managers - California State University at Los Angeles, 1983

Introduction to Human Anatomy and Physiology - University of California at Los Angeles, Extension, 1984

MBA Program, California Coast University